Production of Insulin-Like Growth Factor Binding Proteins (IGFBPs) by Bovine Granulosa and Thecal Cells: Regulation by Metabolic Hormones by Chamberlain, Conni S.
PRODUCTION OF INSULIN-LIKE GROWTH FACTOR
BINDING PROTEINS (IGFBPs) BY BOVINE
GRANULOSA AND TIIECAL CELLS:
REGULATION BY METABOLIC
HORMONES
By
CONNIE S. CHAMBERLAIN
Bachelor of Science
University of Illinois
Champaign-Urbana, Illinois
1995
Submitted to the Faculty of the
Graduate College of the
Oklahoma State University
in partial fulfillment of
the requirements for
the Degree of
MASTER OF SCIENCE
December, 1999
PRODUCTION OF INSULIN-LIKE GROWTH FACTOR
BINDING PROTEINS (IGFBPs) BY BOVINE
GRANULOSA AND THECAL CELLS:
REGULATION BY METABOLIC
HORMONES
Thesis Approved:
k)s~~~
c::R~ uJ~
_---"'w~Q lJdkl 8 ./J!lZfJtLL
Deai of the Graduate College
11
ACKNOWLEDGMENTS
I would like to express my sincere gratitude to Dr. Leon Spicer. I arrived at
Oklahoma State University naive and unenlightened, looking for my trail through life.
Dr. Spicer opened my eyes to the path before me. My resulting journey through the
entanglements of study has led me to a wonderful oasis of research. Dr. Spicer has
sparked my desire to learn and pushed me to work harder to achieve everything
imaginable. I have learned a great deal and will always be indebted.
Dr. Rodney Geisert has been an amazing mentor in which I hold a great deal of
respect. He has gone out on shaky limbs for me which are feats I will never forget. His
desire to see his students succeed is amazing. I am in awe of his unselfish nature. Thank
you, Dr. Geisert for all your help and advice.
I would also like to thank Dr. Robert Wettemann. He is one of the most
vivacious researchers I have come to know. He walks into work like a child walks into a
toy store. His excitement and compassion for his job is exciting to witness.
Well, I must say, this has been a very fulfilling, adventurous, and at times,
difficult experience in which I will always cherish. My duration here has been
supplemented with a number ofgraduate students that I will always remember. If one
walks through life, avoiding the special qualities of others', then life has not been lived to
the fuIJest. Thus, I truly want to thank the graduate students that have passed through
and currently are in my life. They have 'istened to my complaints, my humorless jokes
III
and have made me smile. Thanks.
Finally, I would like to dedicate this thesis to my parents, Wesley and Carolyn
Chamberlain. They have sacrificed much for my ambitions and through it all, they have
been an amazing frame of support. I am truly proud to be their daughter. Thanks mom
and dad.
IV
TABLE OF CONTENTS
C~prer P~e
I. INTRODUCTION 1
II. REVIEW OF LITERATURE 3
Ovarian insulin-like growth factors (IGFs) 3
Ovarian insulin-like growth factor binding proteins (lGFBPs) 6
Chemistry, biology function and ovarian function 6
IGFBP-l 6
IGFBP-2 8
IGFBP-3 10
IGFBP-4 13
IGFBP-S 16
IGFBP-6 20
Honnonal regulation ofIGFBP-l 21
Growth Factors 21
IGF 21
EGF 22
bFGF 22
Gonadotropins 23
FSH 23
LH 25
Steroids 25
Estradiol 25
Cortisol. 26
Metabolic Hormones 27
GH 27
Insulin 28
Glucagon 29
Honnonal regulation ofIGFBP-2 30
Growth Factors 30
IGF 30
EGF 31
bFGF 31
v
Chapter Page
Gonadotropins " 31
FSH 31
LH 31
Steroids 32
Estradiol 32
CortisoL 33
Metabolic Hormones 33
GH 33
Insulin 34
Glucagon 35
Hormonal regulation ofIGFBP-3 35
Growth Factors 35
IGF 35
EGF 36
bFGF 37
Gonadotropins 37
FSH 37
LH 37
Steroids 38
Estradiol 38
Cortisol 38
Metabolic Hormones 39
GH 39
Insulin 40
Glucagon 40
Hormonal regulation ofIGFBP-4 40
Growth Factors 40
IGF 40
EGF 41
bFGF 41
Gonadotropins 42
FSH 42
LH 42
Steroids 43
Estradiol 43
CortisoL 43
Metabolic Hormones 44
GH 44
Insulin 44
Glucagon 4S
Hormonal regulation ofIGFBP-5 45
VI
Chapter Page
Growth Factors 4S
IGF 4S
EGF 46
bFGF 46
Gonadotropins 47
FSH 47
LH 47
Steroids 48
Estradiol 48
Cortisol. .. , " 48
Metabolic Hormones 49
GH 49
Insulin 49
Glucagon 49
Hormonal regulation ofIGFBP-6 50
Growth Factors 50
IGF 50
EGF 50
bFGF 50
Gonadotropins 51
FSH 51
Steroids 51
Estradiol 51
CortisoL 52
Metabolic Hormones 52
GH ' 52
Insulin 52
Glucagon , 53
Proteolysis ofthe IGFBPs 52
IGFBP-2 54
IGFBP-3 56
IGFBP-4 59
IGFBP-5 64
IGFBP-6 66
LITERATURE CITED 69
III. PRODUCTION OF INSULIN-LIKE GROWTH FACTOR BINDING
PROTEINS BY BOVINE GRANULOSA AND THECAL CELLS:
REGULATION BY METABOLIC HORMONES 105
Vll
Chapter Page
Abstract " 105
Introduction........ . .. .. .. .. ... . .. ... . . 106
Materials and methods , 108
Results " 113
Discussion 118
LITERATURE CITED 148
IV. SUMMARY AND CONCLUSIONS 157
Vlll
LIST OF TABLES
Tw~ P~e
1. Binding affinities of the various IGFBPs for IGF-I and IGF-ll 67
2. Percent amino acid homology ofthe IGFBPs across species 68
3. Effect ofLlI. insulin, EGF, and bFGF on thecal cell proliferation
and production ofIGFBP-3, -2 and the 24-kDa IGFBP 143
4. Effect ofFSH, insulin, EGF, and bFGF on granulosa cell proliferation
and production ofthe 20-kDa and 18-kDa IGFBP 144
5. Effect of insulin, glucagon, and cortisol on thecal cell proliferation
and production ofIGFBP-3 and -2 145
6. Summary of the effects ofhonnone treatments on IGFBP production
by bovine thecal cells 146
7. Summary ofthe effects ofhonnone treatments on IGFBP production
by bovine granulosa cells 147
IX
Figure
LIST OF FIGURES
Page
-
1. Panel A: representative example ofcultured thecal ceUs under phase
contrast microscopy. Panel B: representative ligand blot of thecal
cell IGFBP production 128
2. Panel A: representative example of cultured granulosa cells under phase
Contrast microscopy. Panel B: representative ligand blot of granulosa cell
IGFBP production 129
3. Effect of thecal cell density on IGFBP-3 (A), IGFBP-2 (B),
27-29-kDa (C), 24-kDa (D), and 22-kDa (E) IGFBP (arbitrary
densitometric units/lOS cells/24 h) production by thecal cells 130
4. Effect of cell density on the 27-34-kDa (A), 20-kDa (B),
and 18-kDa (C) IGFBP (arbitrary densitometric units/105 cellsl24 h)
production by granulosa cells 133
5. Effect of insulin, LH. EGF, and bFGF on the 27-29-kDa (A)
and 22-kDa (B) IGFBP production (arbitrary densitometric units/lOS
cells/24 h) by thecal cells from large follicles (~ 8 mm) 135
6. Effect of insulin, FSH. EGF, and bFGF on the 27-34-kDa (A)
IGFBP production (arbitrary densitometric units/lOS cells/24 h) by
granulosa cells from small follicles (1-5 mm) 137
7. Effect ofinsuhn, glucagon, and cortisol on the 27-29-kDa (A),
24-kDa (B), and 22-kDa (C) IGFBP production (arbitrary densitometric
units/lOS cells/24 h) by thecal cells from large follicles (~ 8 mm) 139
8. Effect of insulin, glucagon, and cortisol on the 27-34-kDa (A),
20-kDa (B), and 18-kDa (C) IGFBP production (arbitrary densitometric
units/105 cells/24 h) by granulosa cells from small follicles (1-5 nun) 139
x
CHAPTER I
INTRODUCTION
Poor nutrition is an important limiting factor in the reproductive performance of
cattle. When cattle are not sufficiently nourished, they become non-cyclic, consequently
resulting in a loss in efficiency and thus profitability. The loss in efficiency is due to a
down-regulation ofhormonal function. Insulin-like growth factor-I (IGF-I) is one of the
hormones adversely affected by reduced nutrient intake. IGF-I stimulates bovine ovarian
granulosa and thecal cell growth and differentiation in vitro (Spicer et al., 1993; Spicer
and Echternkamp, 1995; Stewart et al., 1995). Bound to IGFs are the high-affinity
transport proteins, the insulin-like growth factor binding proteins (IGFBP), which alter
bioavailability ofIGF. Plasma IGFBP concentrations increase in non-cyclic cattle.
Likewise, in 1991, Bicsak et al. found that the IGFBPs inhibited ovulation in rats.
Therefore, IGF and the IGFBPs have been proposed to be important regulators of
follicular growth and development in cattle (Spicer and Echternkamp, 1995).
At present, little information concerning ovarian IGFBP production is available.
Low molecular weight (MW) IGFBPs, IGFBP-2, 29-kDa and 22-kDa IGFBPs, are
negatively correlated with follicular fluid concentrations ofIGF-I in cattle (Echtemkamp
et aI., 1994). Thus, growing antral follicles have decreased
2concentrations of the low MW IGFBPs, making IGF-I more bioavailable. Conversely,
atretic foUicles have increased concentrations of the low MW IGFBPs making IGF-I less
bioavailable. In contrast, IGFBP-3 is involved in maintaining intrafoUicular IGF-I
concentrations (Echternkamp et at, 1994). Because IGFBP production is influenced not
only by nonna! follicular development, but by factors such as poor nutrition, studies
focused on these proteins may find new methods for improved fertility. Thus, the
objective of this study was to determine the hormonal regulation ofIGFBP production by
bovine granulosa and thecal cells, with specific focus on the effects of insulin, luteinizing
hormone (LH), follicle stimulating hormone (FSH), epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF), cortisol, and glucagon on IGFBP production.
CHAPTERll
REVIEW OF LITERATURE
OVARIAN INSULIN-LIKE GROWTH FACTORS (IGFs)
The insulin-like growth factors (IGF-I and -II) are single chain polypeptides
consisting of an intact C-peptide and three intramolecular disulfide bonds, which are
structurally similar to proinsulin. The amino acid sequence composing IGF-J and -II are
highly homologous across species. For example, the amino acid sequence in sheep, pigs,
humans, and rats are 990,/0, 100%, 100%, and 96% homologous to bovine IGF-I,
respectively (for review see, Spicer and Echternkamp, 1995). Likewise bovine IGF-II is
99014», 97%, 96% and 96% homologous to the ovine, porcine, human and rat, respectively
(for review see, Spicer and Echtemkamp, 1995). These highly conserved growth factors
are present in many tissue fluids and peripheraI circulation (Rosenfeld et aI., 1996).
The activity ofIGF-I is modulated by high affinity type-I IGF receptors (Nissely
et al., 1985). The type-I receptor also binds IGF-II and insulin, but only with 10% and
.3% cross-reactivity, respectively (Baranao and Hammond, 1984; Davoren et aI., 1986;
Gates et al., 1987; Adashi et aI., 1988b; Sauerwein et aI., 1992). Like insulin, IGF-I acts
through the tyrosine kinase pathway which links to the mitogen-activated protein kinase
signal transduction system and transduces the cellular signal to the nucleus. The IGF-II
receptor consists of a single glycosylated protein chain, approximately 250 kOa. This
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IGF type II receptor is identical to the mannose-6-phosphate r«eptor (Kiess et
aI., 1994). These receptors have been localized within the mammalian ovary.
The IGFs have been identified in a variety of tissues. Within the ovary, IGF-I
mRNA has been detected in cultured rat (Adashi et aI., 1989; Oliver et aI., 1989),
porcine (Hatey et aI., 1992), and bovine (Spicer and Echtemkamp, 1995) granulosa cells,
ovine CL (Einspanier et aI., 1990; Perks et aI., 1995) and bovine thecal cells (Spicer et
aI., 1993). Gene expression for IGF-I has not been detected in human (Voutilainen and
Miller, 1987; EI-Roeiy et aI., 1993; Geisthovel et aI., 1989; Hernandez et al., 1992)
granulosa cells or ovine follicles (perks et aI., 1995; Spicer et aI., 1995). However. gene
expression for IGF-ll is present in human stromal, thecal, and granulosa cells
(Voutilainen et a1., 1996) and ovine (perks et aI., 1995) thecal cells. Further
observations have indicated that the greatest gene expression ofIGF-1i is detected in the
human granulosa cells of the large follicle with expression increasing during follicular
growth, likely due to the stimulatory effect of the gonadotropins (Voutilainen et aI.,
1996). Similar to IGF-II mRNA levels in human granulosa cells, concentrations ofIGF-I
increase with follicular growth in cattle (Spicer et a1., 1988; Spicer and Enright, 1991)
and pigs (Bryan et al., 1989; Spicer et a1., 1992). Likewise the IGF-I receptor is located
in granulosa cells of rats (Oliver et a1., 1989) and cattle (Spicer et aI., 1994; Stewart et
aI., 1996), and in pigs (Otani et aI., 1985; Caubo and Tonetta, 1989), cattle (Stewart et
aI., 1995; 1996) and mice (Hernandez et aI., 1988a,b; Cara and Rosenfield, 1988) thecal
cells. The IGF-I gene is expressed in human thecal cells (Bergh et aI., 1993; El-Roeiy et
aI., 1993; 1994).
-Components of the IGFaxis play an important role in cellular proliferation and
follicular development. Within the ovary, IGFs increase cell proliferation in cultures of
human (Erickson et aI., 1990; Olsson et aI., 1990), ovine (Monniaux and Pisselet, 1992),
bovine (Savion et aI., 1981; Spicer et aI., 1993), rat (Adashi et aI., 1985) and porcine
(Baranao and Hammond, 1984; Veldhuis and Furlanetto, 1985; Maruo et aI., 1988;
Kamada et aI., 1992) granulosa cells and bovine thecal cells (Stewart et aI., 1995). IGFs
also act synergistically with gonadotropins to stimulate aromatase activity (Adashi et aI.,
1985; Kamada et aI., 1992) and progesterone biosynthesis (Savion et aI., 1981; Adashi et
aI., 1985; Monniaux and Pisselet. 1992), as well as to regulate fonnation ofLHlhCG
receptors (Adashi et al., 1985; Davoren et at., 1985; 1986) in granulosa cell cultures.
Likewise, within cultured thecal and secondary interstitial cells, IGF-I and LH
synergistically stimulate androgen production (Magoffin and Erickson, 1988; Cara and
Rosenfeld, 1988; Magoffin et aI., 1990; Hernandez et al., 1988b). Hormones regulate
IGF-I receptors. EGF, estradiol, and FSH increased and bFGF decreased the number of
IGF-I receptors in granulosa cells of small bovine follicles (Spicer et aI., 1994).
Similarly, LH had no effect, whereas bFGF decreased the number ofIGF-I receptors in
thecal cells oflarge bovine follicles (Spicer and Stewart, 1996). In the same experiment,
LH or progesterone had no effect on the concentration ofIGF-receptors (Spicer et aI.,
1994). Hormones such as estradiol (Veldhuis et aI., 1986) and dexamethasone (Urban et
aI., 1994) also increase IGF-I receptor numbers in porcine granulosa cells.
Another factor involved in the IGFaxis is the insulin-like growth factor binding
proteins. Each IGFBP preferentially binds to IGF-I and(or) -0 at different affinities to
regulate the transport and hioavailability of the IGFs (Table 1). Currently six IGFBPs
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have been cloned and sequenced with each IGFBP exhibiting high homology across
species (Table 2). Estradiol concentrations are negatively correlated with IGFBP-2, the
27-29-kDa IGFBP (presumably IGFBP-5), and 24-kDa IGFBP (presumably IGFBP-4)
in ovine and bovine follicular fluid, whereas IGFBP-3 is not (Spicer et ai., 1995; Stewart
et ai., 1996). IGFBP-2, -3, -4, and -5 attenuate IGF-I- and FSH-induced estradiol
synthesis in cultured rat, bovine, and human granulosa cells by sequestering IGF-I (Ui et
aI., 1989; Mason et aI., 1992; Liu et aI., 1993; Spicer and Chamberlain, 1999). Thus,
throughout the estrous cycle IGFIIGFBPs are continually modified with the changing
endocrine profiles, demonstrating the complexity of the IGFaxis.
OVARIAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS
(IGFBPs)
Chemistry, biological function and ovarian function
IGFBP-l
IGFBP-l is a nonglycosylated, acid stable protein (Ooi and Herington, 1988;
Baxter and Martin, 1989a) with a molecular weight of30-31 kDa (Shimasaki and Ling,
1991) that binds IGF-II with greater affinity than IGF-I (Table I). The protein sequence
of IGFBP-l shares 68-72% homology among species (Table 2) and contains 12 N-
terminal and 6-C tenninal cysteine residues, both ofwhich are required for optimallGF-I
and -IT binding (Lee et aI., 1997). IGFBP-l is synthesized primarily in the liver (Lee et
al., 1993) and is present in amniotic fluid (Giudice et aI., 1991) as well as plasma
(Rabinovici et aI., 1997) of humans. IGFBP-I is also present in a number of human
ovarian components such as preovulatory follicular fluid, corpora lutea (CL; Seppala et
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aI., 1984), as well as luteal cells ofhyperstimulated preovulatory follicles (Seppala et aI.,
1984), and cultured thecal (Mason et aI., 1991), stromal (Mason et aI., 1991) and
luteinized granulosa ceUs (Suikkari et aI., 1989; Jalkanen et aI., 1989; Giudice et aI.,
1991). Human IGFBP-l mRNA, but not the protein, was only expressed in cultured
thecal ceUs whereas both the protein (Jalkanen et ai., 1989) and mRNA (EI-Roeiy et aI.,
1994) for IGFBP-l were detected in granulosa cells. Moreover, concentrations of
IGFBP-l are greater in follicular fluid than serum (Hartshorne et aI., 1990).
IGFBP-l, along with IGF-I and -II, is involved in a complex system that
regulates the menstrual cycle, ovulation, decidualization, blastocyst implantation, and
fetal growth (for review see, Lee et al., 1993; Lee et aI., 1997), working possibly
through the adenylate-cyclase and protein-kinase-C-dependent pathways (Jalkanen et aI.,
1989). Within the ovary, IGFBP-l is associated with luteinized granulosa cells of the
CL, which suggests IGFBP-l is involved with luteinization of the granulosa cells
(Jalkanen et aI., 1989; Suikkari et aI., 1989; Giudice et al., 1990a; Hartshorne et aI.,
1990) and regulation of the CL (Van Dessel et al., 1996). During the preovulatory
stage, IGFBP-l concentrations in serum (Martikainen et aI., 1991) and follicular fluid
(Van Dessel et aI., 1996) are significantly increased, suggesting that IGFBP-l may
regulate follicular growth and maturation possibly by mediating the actions ofIGF-I.
Thecal cell androgen production is controlled by IGF-I in synergy with LH. Thus, it is
possible that during the follicular phase, IGFBP-l inhibits IGF-I-induced androgen
production by thecal cells and thus prevents follicular atresia (Nobels and Dewailly,
1992). However, due to post-translational modifications, the actions ofIGFBP-l are not
clear. IGFBP-l can both inhibit and stimulate IGF-binding to cell surface receptors,
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thereby controlling IGF-mediated mitogenic and metabolic actions in various tissues,
including the ovary (Holst et aI., 1997). The inhibitory form ofIGFBP-l is
phosphorylated. This phosphorylation ofIGFBP-l causes a six-fold increase in its
affinity for IGF-I (Jones et aI., 1991). Therefore. when the affinity ofIGFBP-l for IGF-I
is substantially higher than that of the receptor, the equilibrium will favor the binding of
IGF-I by the binding proteins in preference to binding of its receptor (Clemmons. 1993).
Conversely, dephosphorylated IGFBP-l has a lower affinity for IGF-I, thus allowing
more interaction ofIGF-I with its receptor (Clemmons. 1993).
IGFBP-2
IGFBP-2, which binds to both IGF-I and -II with high affinity (Roghani et at.,
1991), is a nonglycosylated, acid stable (Ooi and Herington 1988; Baxter and Martin,
1989a) protein with a molecular mass of approximately 29-40 kDa. The amino acid
sequence ofIGFBP-2 exhibits 64-92% homology among species (Table 2). This is the
major binding protein in cerebrospinal fluid and the central nervous system (Binoux et
aI., 1982; Baxter et aI., 1989a; Rosenfeld et aI., 1989), human ovary (Voutilainen et al.,
1996), and is aIso present in adult rat serum (Shimasaki et al., 1991b), human milk and
seminal plasma (Binoux et aI., 1991a,b; Blum et aI., 1993). IGFBP-2 gene expression is
also localized in the bovine endometrium, and to a lesser extent, myometrium (Kirby et
aI., 1996). In general, IGFBP-2 binds IGF-II with greater affinity than IGF-I (Table 1)
and appears to inhibit IGF action, primarily IGF-II (Reeve et aI., 1993). In bovine thecal
cells, IGFBP-2 inhibits IGF-I-induced cell proliferation and steroidogenesis (Spicer et aI.,
1997). However, within certain cell-types, IGFBP-2 does have a modest stimulatory
influence on IGF action (Bar et aI., 1989).
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IGFBP-2 is abundant in ovarian tissues ofall species examined, but its cellular
localization varies among species (Zhou et al., 1996). Within the ovary, IGFBP-2 mRNA
has been localized in the granulosa and thecal cells and CL ofpigs (Samaru et aI., 1992)
and sheep (perks and Wathes, 1996), ovine stromal (perks and Wathes, 1996) and the
thecal-interstitial and secondary interstitial cells of the rat (Nakatani et aI., 1991). In
humans, IGFBP-2 protein (Cataldo et al., 1993; Mason et aI., 1996) and mRNA
(Voutilainen et al., 1996) has been detected in the stromal, granulosa and thecal cells.
Bovine IGFBP-2 protein (Funston et al., 1996) is also located in the granulosa and the
thecal cells but gene expression has only been detected in the CL (Kirby et al., 1996) and
granulosa cells (Yuan et al., 1998). Specifically, bovine IGFBP-2 mRNA was present in
granulosa cells of the early and mid-dominant follicle (Yuan et al., 1998) although the
protein level appeared to decrease in dominant follicles (Stewart et al., 1996). In the
case of the human, IGFBP-2 mRNA is expressed more in the thecal tissue than in the
granulosa cells or stromal tissue of the large (14 mm) follicle (Voutilainen et aI., 1996).
The reverse is true in the small (11 mm) human follicle where IGFBP-2 mRNA is higher
in the granulosa cells than the larger follicle or thecal compartment (Voutilainen et aI.,
1996). It appears that IGFBP-2 production decreases as granulosa cells differentiate and
luteinize, and aromatase activity increases. This and other research suggests IGFBP-2
behaves in an autocrine manner to regulate individual follicle response to trophic factors
(Samaras et aI., 1992).
In human (Cwyfan Hughes et aI., 1997) and bovine (Stanko et aI., 1994)
follicular fluid, IGFBP-2 is denoted by three bands, two of which correspond to non-
IGF-binding proteolytic fragments. In the human, the smallest band (23-kDa), detected
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by immunoblotting, represents the major form ofthis binding protein in the fluid of
dominant follicles (Cwyfan Hughes et aI., 1997). In contrast, only intact IGFBP-2 (34-
leDa) is located in conditioned medium from human granulosa cells, thecal, and stromal
explants (Cwyfan Hughes et aI., 1997). However, both the intact (34-kDa) and a 25.5-
leDa band are seen in the circulation ofwomen (Cwyfan-Hughes et aI., 1997). The
discovery of lower molecular weight forms ofIGFBP-2 in follicular fluid suggests a
specific mechanism for modulating IGFBP-2, since the 23-leDa is not found in any other
compartment of the human ovary, nor is it the same as that found in the circulation. It is
possible that the 23-kDa band is a result of proteolysis ofIGFBP-2, which aI,so has been
demonstrated in ovine follicular fluid (Besnard et aI., 1996b). Proteolysis of the IGFBPs
is discussed in more detail in a later section of this review.
IGFBP-3
IGFBP-3 is a N-glycosylated (Zapf et aI., 1988) 150 leDa binding protein
consisting of an acid-labile 85 kDa subunit, an IGF peptide, and a binding subunit
(Baxter and Martin 1989b; Rosenfeld et aI., 1990; Lamson et aI., 1991) which exists in
two alternatively glycosylated forms with molecular weights ofapproximately 44- and
42-kDa. These two glycoprotein forms decrease in size to a single species upon
deglycosylation (Liu et al., 1990), the amino acid sequence ofwhich is highly conserved
among species (Table 2). Absence of the carbohydrate side chains may not permit
IGFBP-3 to associate with cell surfaces (McCusker et aI., 1990). Inununoblots revealed
both the intact doublet (43- and 40-kDa) and a lower molecular weight band (29-leDa)
were present in medium conditioned by thecal extracts as well as atretic follicles in the
human (Cwyfan-Hughes et aI., 1997). Ofthe six IGFBPs, approximately 75-800,/0 of
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liver-derived IGFBP-3 binds to IGFs in the circulation (Guier et al., 1989~ zapf et al.,
1990; Baxter, 1994), but not to insulin (Clemmons et al., 1986). Binding affinity of
IGFBP-3 for IGF-I and -IT are similar (Table 1). Thus, this ternary complex acts as a
circulating reservoir ofIGFs and regulates the delivery of the IGFs to target tissues. The
half-life (i.e., metabolic clearance) ofIGF-I bound to this complex is 3-6 h whereas free
IGF-I has a half life of20-30 min (Zapfet al" 1986; Davis et al., 1989~ Guier et al.,
1989~ Hodgkinson et aI., 1989; Bassett et aI., 1990). Also by sequestering IGF-I and
preventing interaction with its receptor, IGFBP-3 can inhibit IGF-I bioactivity.
DeMellow and Baxter (1988) demonstrated that when cultured human fibroblasts are
treated simultaneously with IGF-I and IGFBP-3, IGFBP-3 inhibits IGF-I-stirnulated
proliferation in a dose-dependent manner. Furthennore, when cultured human
fibroblasts are first treated with IGFBP-3 for 24 h, followed by IGF-I, IGF-I-induced cell
proliferation increased (DeMellow and Baxter, 1988). An inhibitory action ofIGFBP-3
on IGF-I-induced steroidogenesis and proliferation of bovine granulosa (Spicer and
Chamberlain, 1999) and thecal (Spicer et aI., 1997) cells has been confirmed. IGFBP-3
also inhibits gonadotropin-induced steroid production by rat (Ui et al., 1989) and human
(Mason et aI., 1992; San Roman and Magoffin, 1993) granulosa cells. Thus, ovarian
IGFBP-3, which has been shown to neutralize gonadotropin and IGF-I action, likely
works by its ability to sequester IGFs (Baranao and Hammond, 1984; Hammond et aI.,
1988; Kamada et at, 1992; Spicer et aI., 1997). Conversely, an increase in IGF-I action
has been attributed to cell surface-associated IGFBP-3 (Conover, 1992). For example,
in vitro work has shown that in fetal human fibroblasts and porcine smooth muscle cells,
IGFBP-3 enhances IGF-I binding to receptors (McCusker et ai., 1991a).
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IGFBP-3 has been located in a variety of tissues, including the liver, testis, and
ovary. Moreover, IGFBP-3 gene expression has been detected in the bovine
endometrium (Kirby et aI., 1996). Within the ovarian compartment, IGFBP-3 gene
expression is not detected in the rat granulosa or thecal cells, but the IGFBP-3 mRNA
has been found in the CL (Nakatani et aI., 1991) undergoing regression (Erickson et aI.,
1993a). Similar localization of ovarian porcine IGFBP-3 mRNA (Mondschein et aI.,
1990; Samaras et aI., 1992) comply with the rat except that low levels ofIGFBP-3
mRNA were detected in thecal cells (Samaras et aI., 1994). Contrary to the rat, human
IGFBP-3 mRNA was detected in cultured granulosa cells (Giudice et aI., 1991) and was
induced in cultured thecal cells (El-Roeiy et aI., 1994; Voutilainen et al., 1996). A
modest amount ofIGFBP-3 mRNA was also detected in bovine granulosa cells whereas
none was found in the thecal cells from small antral follicles (Yuan et aI., 1998).
Furthermore, IGFBP-3 protein has been localized in both human (Cataldo et aI., 1993)
and porcine (Mondschein et aI., 1990) granulosa cells, as well as in the human thecal and
stromal tissue (Hughes et aI., 1997). The concentration ofIGFBP-3 in follicular fluid is
constant throughout the estrous cycle as demonstrated in cows (Echtemkamp et al.,
1994a; de la Sota, et aI., 1996; Funston et aI., 1996; Stewart et aI., 1996), sheep
(Monget et aI., 1993; Spicer et aI., 1995), and pigs (Grimes et aI., 1994b). It is also
constant during the human menstrual cycle (Cataldo and Giudice, 1992b; Huang et aI.,
1994). However, San Roman and Magoffin (1993) have found that as human follicles
reach the estrogenic ovulatory phase, IGFBP-3 concentrations decrease. Moreover,
IGFBP-3 follicular levels are comparable to those seen in serum (Cataldo et al., 1992b;
Stanko et aI., 1994; Stewart et aI., 1996). This indicates that intrafollicularIGFBP-3
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originates from an endocrine source. As mentioned, the liver is the main site ofgene
expression and secretion ofIGFBP-3, which then forms large complexes in the serum
(Wood et al., 1988). Prior to ovulation, vascularization of the follicle is increased
(Okuda et al., 1983) which would potentiate the passage ofIGFBP-3 from serum into
follicular fluid. It is therefore possible that follicular fluid IGFBP-3 is derived from the
peripheral circulation, although, some ofIGFBP-3 may originate from ovarian cells
(Cataldo et al., 1992b). Furthermore, luteal IGFBP-3 may act in a paracrine manner to
limit follicular growth during the luteal phase (Samaras et al., 1992).
IGFBP-4
The identity ofIGFBP-4 can not be resolved conclusively, but it appears as a 22-
24-kDa nonglycosylated binding protein that contains one potential asparagine-linked
glycosylation site (Shimasaki et al., 1990) and binds IGF-I and IGF-II with equal affinity
(Table 1). IGFBP-4 also consists ofan approximately 28-kDa glycosylated protein
(Fielder et al., 1990), the amino acid sequence ofwhich is highly conserved among
species (Table 2). IGFBP-4 was originally isolated from the conditioned medium of
human bone cells and rat serum (LaTour et aI., 1990; Shimasaki et aI., 1990) and has
since been identified in body fluids (i.e., seminal plasma), and conditioned media of
several cell lines, including normal human osteoblast-like cells (Mohan et al., 1989),
fibroblasts (Camacho-Hubner et a1., 1992), endometrial stromal cells (Irwin et aI., 1995)
and neuroblastoma cells (Fielder et aI., 1990; Cheung et aI., 1991).
Human IGFBP-4 is primarily localized in granulosa cells of atretic follicles,
(Cataldo et aI., 1993; Voutilainen et aI., 1996) and its mRNA is expressed in increasing
levels during atresia (Nakatani et aI., 1991; Erickson et aI., 1992a; Erickson et a1.,
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1992b). IGFBP-4 has also been detected in the CL and oocyte at the primordial stage of
follicular growth and persists in the preantral and antral stage offollicular development
(peng et aI., 1996). Using human thecal-conditioned medium from dominant follicles,
Cwyfan-Hughes et aI. (1997) demonstrated the presence of the non-glycosylated IGFBP-
4 (24-kDa) along with two possible fragments ofIGFBP-4 (16.5- and I5-leDa) which are
not visible by ligand blotting. Moreover. a glycosylated intact IGFBP-4 (26-lcDa) was
found in human follicular fluid (Cwyfan-Hughes et ai.• 1997). HullWl IGFBP-4 mRNA
is also moderately expressed in the thecal, stromal, and granulosa cells oflarge (14 mm)
preantral follicles, but is 50% more abundant in granulosa cells of smaller follicles (11
rom; Voutilainen et ai., 1996). Interestingly, inununostaining revealed that in human
antral follicles from polycystic ovaries without hyperinsulinemia, IGFBP-4 is more
prominent in granulosa cells as compared to thecal cells during the early follicular phase
(peng et aI., 1996). However. IGFBP-4 is more prominent in thecal cells compared to
granulosa cells in women suffering from polycystic ovarian syndrome with
hyperinsulinemia during the early follicular phase (peng et a1., 1996).
Similar to the human, IGFBP-4 is prominent in rat granulosa cells ofatretic
follicles (Liu et a1., 1993; Choi et al., 1996). However, rat IGFBP-4 mRNA was not
detected in oocytes, thecal interstitial cells, or the theca externa (Erickson et a1., 1992a)
but a weak and variable signal for mRNA has been detected in dominant follicles
(Erickson et a1., 1992a). IGFBP-4 mRNA is present in ovine thecal cells, and to an
extent, granulosa cells ofhealthy follicles, with no significant differences between small
and large follicles (Besnard et aI., 1996a). However, expression of ovine IGFBP-4
mRNA is greater in thecal cells from smaHlate atretic, compared with small nonnal and
-small atretic follicles (Besnard et aI., 1996a). In comparison, IGFBP-4 is detected more
in atretic and small healthy follicles compared to large healthy follicles in pigs (Besnard
et aI.• 1997). However. Zhou et aI. (1996) reported that IGFBP-4 mRNA wu not
present in small follicles of pigs. Rather. IGFBP-4 mRNA in pigs first appears in thecal
cells of medium sized growing follicles. and does not appear in the granulosa cells of the
dominant follicles until the late follicular phase, when luteinization is evident (Gadsby et
aI., 1996; Zhou et aI., 1996). IGFBP-4 mRNA is also present in the porcine CL (Zhou
et aI., 1996).
Follicular fluid from large estrogen-inactive, medium and small bovine follicles
contain detectable levels ofIGFBP-4 (Funston et aI., 1996). Stewart et aI. (1996) found
a decrease in IGFBP-4 activity in early dominant follicles when compared with
subordinate small and large follicles of cattle. Moreover, the percentage offollicular
fluid to plasma IGFBP-4 activity in small follicles resulted in a 131% difference,
suggesting ovarian production of IGFBP-4 (Stewart et al.. 1996). Because IGFBP-4 is
significantly increased in nonnal progesterone/androgen-dominant follicular fluid
compared with estrogen-dominant follicular fluid (Cataldo and Giudice, 1992a; Cataldo
and Giudice, 1992b), gonadotropin-dependent maturation of follicles may be due to
inhibition of the expression and virtual disappearance of granulosa cell-derived IGFBP-4.
Consequently, high IGFBP-4, like other IGFBPs, may be an inhibitor ofIGF-I action in
small and large estrogen-i.nactive follicles. Similar to other IGFBPs, IGFBP-4 binds to
IGF thereby preventing the interaction of the IGFs with their receptors. By inhibiting
IGF action in the ovary, IGFBP-4 may inhibit follicular development and induce atresia.
For instance, IGFBP-4 inhibits IGF-I-stimulated estradiol release by rat (Liu et aI., 1993)
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and human (Iwashita et aI., 1996) granulosa cells in vitro. Likewise, addition ofIGFBP-
4 to cultured rat granulosa cells in the presence of either 100 or 30 nglml ofFSH
inhibited estradiol production (Vi et aI., 1989; Liu et aI., 1993). However, because a
decrease in intrafollicular IGFBP-4 levels during follicular growth is not associated with
a decrease in expression in the corresponding mRNA, the absence of IGFBP-4 protein in
follicular fluid from the preovulatory follicles may be attributed to proteolytic
degradation (see later section on IGFBP proteolysis; Fowlkes et aI., 1995).
IGFBP-5
IGFBP-5 is a 25 amino acid O-linked glycosylated (Conover and Kiefer, 1993)
binding protein with a molecular weight of approximately 29-31 kDa (Shimasaki and
Ling, 1991; Shimasaki et aI., 1991b). The amino acid sequence ofIGFBP-5 is highly
homologous among mammals (Table 2). Like the other IGFBPs, IGFBP-5 contains 18
conserved cysteines (Jones and Clemmons, 1995) which may be involved in specific
binding to the IGFs, with IGF-II having a greater affinity than IGF-I for IGFBP-5 (Table
I). A soluble form ofIGFBP-5 has no Asn-linked glycosylation sites and does not
contain the Arg-Gly-Asp which is believed to facilitate binding to cell surface integrin
receptors (Ruoslahti et a1., 1987). However, IGFBP-5 also consists of a sequence of 13
highly basic amino acids near the carboxyl terminus which may facilitate binding to the
extracellular matrix and decrease its affinity for IGF-I (Clemmons, 1993). This 21-kDa
extracellular matrix-bound IGFBP is the more predominant form ofIGFBP-5
(Clemmons, 1993).
IGFBP-5 mRNA has been identified in the rat liver, brain, lung, heart, spleen,
stomach, kidney, adrenal, intestine and testis homogenates (Erickson et aI., 1992b), as
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well as in human fibroblasts (Camacho-Hubner et al., 1992) and osteoblast (Conover and
Kiefer 1993~ Canalis and Gabbitas, 1995) cells. Within the rat ovary, IGFBP-S mRNA is
expressed in atretic granulosa cells, secondary interstitial cells, CL, and surface
epithelium (Erickson et al., 1992b). Erickson and co-workers (1 992b) found that rat
IGFBP-5 mRNA is constantly expressed in the surface epithelium. During proestrus, the
message to IGFBP-5 is present in granulosa cells of a few atretic preantral follicles.
Around the onset of estrus, the IGFBP-5 gene expression is very prominent in almost
every atretic preantral follicle. In addition, gene expression for IGFBP-5 is detected in
granulosa cells of some atretic antral (graaflan) follicles and secondary interstitial cells.
Finally, during diestrus I and II, IGFBP-5 mRNA is decreased and essentially absent in
all follicles (healthy and atretic) and the secondary interstitial cells. No evidence of
IGFBP-5 mRNA was found in rat granulosa cells ofdominant folJicles, oocytes, thecal
interstitial cells, thecal externa, stromal or smooth muscle cells regardless of the stage of
the estrous cycle (Erickson et al., 1992b). However, using an antibody specific to rat
IGFBP-5, Liu et aI. (1993) demonstrated that rat cultured granulosa cells produce
IGFBP-5. Thus, these results reveal tissue-specific expression of the rat IGFBP-5 gene
as well as stage (and perhaps hormone) dependent regulation ofovarian IGFBP-5
mRNA. In humans, IGFBP-5 mRNA has been localized within the ovarian
compartment. Within the granulosa (Zhou et aI., 1993~ Voutilainen et aI., 1996) and
thecal cells (Voutilainen et aI., 1996) IGFBP-5 mRNA has been detected, but is primarily
localized in the ovarian stroma (Zhou et aI., 1993).
A 30-kDa IGFBP in pigs has tentatively been identified as IGFBP-5. Amounts of
IGFBP-5 are greater in porcine small healthy follicles than large healthy follicles, and in
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atretic compared to healthy follicles, whatever the follicle size (Besnard et aI., 1997). In
addition, the granulosa cells have been found to secrete IGFBP-5 (Grimes et al., 1994a).
Although not abundant, ovarian IGFBP-5 mRNA is also present in the surface
epithelium, blood vessels, luteal capillaries, connective tissue and vasculature of pig
ovaries (Zhou et al., 1996). IGFBP-5 mRNA, however, has not been found in porcine
follicles (Zhou et al., 1996). This evidence suggests that IGFBP-5 is not critical in
follicular selection or function, at least in the pig.
Similar to the pig, a 30-kDa IGFBP produced by large and small granulosa cells,
in vitro, has a suggested identity ofIGFBP-5 in sheep (Armstrong et aI., 1996). Ovine
IGFBP-5 mRNA is primarily present in the granulosa cells of atretic follicles, and the
thecal cells of healthy follicles (Besnard et al., 1996a). In follicular fluid, IGFBP-5
levels, detected by ligand blotting, are greater in small versus large ovine follicles (Spicer
et al., 1995). In follicular fluid, IGFBP-5 levels, detected by ligand blotting, are greater
in small versus large ovine follicles (Spicer et aI., 1995). Therefore, atresia oflarge
follicles is associated with an increase in intrafollicular IGFBP-5 levels and an increase in
IGFBP-5 mRNA expression in granulosa cells and a slight decrease in IGFBP-5 mRNA
expression in thecal cells (Besnard et al., 1996a).
IGFBP-5 has also been tentatively identified in cattle, using irwnunoblotting
techniques, as a doublet in follicular fluid with a molecular range of 29-31-kDa (Funston
et aI., 1996). In addition, Stanko et al. (1994) reported a 21-kDa fragment in bovine
follicular fluid that corresponds to IGFBP-5. Stewart et aI. (1996) who also reported a
single band representing IGFBP-5 (29-kDa), found that during the first follicular wave of
the bovine estrous cycle, IGFBP-5 activity was greater in subordinate small «6 nun in
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diameter) and large (~6 mm in diameter) follicles compared with early dominant follicles
(Stewart et al. 1996) which has been confinned by others (Carolan et al., 1996; de la
Sota et aI., 1996).
Due to proteolysis, the intact IGFBP-5 is degraded to smaller molecular weight
fragments ofapproximately 16-20-kDa. However, the association ofIGFs may stimulate
the increase in IGFBP-S. Binding ofIGF to IGFBP-S protects it from proteolysis by
FSH-treated granulosa cells (Fielder et aI., 1993). Proteolysis ofIGFBP-S is discussed
in detail in a later section. Moreover, the addition ofIGFBP-5 to cultured rat granulosa
cells in the presence of either 100 or 30 nglml ofFSH inhibited estradiol production (Liu
et aI., 1993). These studies imply that during follicular growth, IGFBP-5 production is
maintained or increases when bound to IGF while FSH levels are increasing. However,
the effect ofIGFBP-5 on IGF action remains contradictory. Kiefer et aI. (1992)
demonstrated that rhIGFBP-5 inhibited IGF-stimulated DNA synthesis in human
osteoblastic cells. In contrast, Andress and Birnbaum (1991) found that partially purified
IGFBP-5 enhanced IGF-stimulated osteoblast mitogenesis. These conflicting results
could be due to the nature ofIGFBP-S. Kiefer et aI. (1992) utilized intact IGFBP-5
whereas Andress and Birnbaum (1991) used a 23-kDa form ofIGFBP-5. This 23-kDa
protein may just represent a proteolytic fragment that is functionally distinct from
IGFBP-5. IGFBP-5 fragments have a decreased affinity for IGF and therefore increases
IGF bioavailability. In addition, when IGFBP-5 is associated with the extracellular
matrix in fibroblasts and bone (Bautista et a1., 1991; Jones et aI., 1992), it has a
decreased affinity for the IGF peptides and stimulates IGF action. Therefore, these
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studies infer that soluble IGFBP-5 may inhibit, whereas matrix-associated IGFBP-5 may
enhance IGF action (Conover and Kiefer, 1993).
IGFBP-6
IGFBP-6 is an approximately 28-32-lcDa binding protein found primarily in
hUl1WlS and rats. IGFBP-6, which binds IGF-I1 with the highest affinity of the binding
proteins (Table 1), also binds IGF-I except with a 20-100 fold lower affinity (Forbes et
aI., 1990; Martin et al., 1990). IGFBP-6 has been purified from various tissues,
including human cerebrospinal fluid (Bach et aI., 1992; Bach et aI., 1994), serum (Zapf et
aI., 1990), media conditioned by transformed fibroblasts (Martin et aI., 1990),
keratinocytes (Kato et aI., 1995), prostate cancer cells (Srinivasan et aI., 1996),
osteoblasts (Gabbitas and Canalis, 1997), bovine mammary epithelial cells (Cohick and
Turner, 1998) and retinal pigment epithelial cells (Feldman and Randolph, 1994). Within
the ovary, IGFBP-6 gene has been localized in the rat theca-interstitial compartment
(Rohan et al, 1993) and appears to be produced by rat granulosa cells. Using RT-PCR,
human IGFBP-6 mRNA is found in the thecal, stromal, and granulosa cells (Voutilainen
et al., 1996). In addition, Shimasaki et al. (1990) found IGFBP-6 in porcine follicular
fluid. However, it is not found in porcine granulosa cells, thus suggesting that IGFBP-6
is produced by other ovarian cells in the pig.
The structure ofIGFBP-6 is not phosphorylated, unlike IGFBP-l, -3, and -5,
which may be serine-phosphorylated. Furthermore, IGFBP-61acks 2 and 4 of the N-
terminal cysteines in the human and rat, respectively, that are normally conserved in
IGFBP-l through -5 (Shimasaki et al., 1991a) and are believed to be involved with IGF-
binding (Spencer and Chan, 1995). In addition, IGFBP-6 is an O-glycosylated protein.
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Human IGFBP-6 contains an additional N-glycosylation area, but the site is not
glycosylated. As previously mentioned, glycosylation of the binding proteins not only
serve for ligand binding, but also facilitate cellular processing, protection from
proteolysis, modulation ofbinding to structural biomolecules including membrane and
extracellular matrix components and retardation of in vivo clearance. Therefore,
glycosylation ofIGFBP-6 may prolong its half-life, due to decreased clearance by
specific receptors and also, protect the protein from proteolysis. However,
deglycosylation of human IGFBP-6 has no effect on IGF binding, so it would appear that
glycosylation has no role in IGF-II binding by IGFBP-6 (Neumann et aI., 1998). Unlike
the other IGFBPs, rhIGFBP-6 has no effect on FSH-induced steroid production by rat·
granulosa cells (Rohan et al., 1993).
Hormonal Regulation ofIGFBP-l
Growth Facton
IGF. IGFs are produced within the ovarian follicle, stimulate mitogenesis and
steroidogenesis, and regulate IGFBP activity. Addition ofIGF-I or -II to human
granulosa-luteal cells reduces IGFBP-l levels significantly (Dor et aI., 1992~ Poretsky et
al., 1996). The potency ofIGF-I and -II were similar but much greater than that of
insulin (poretsky et aI., 1996). Interestingly, IGFBP-l inhibits IGF-I and -II-stimulated
bovine granulosa cell division (Lavranos et aI., 1996). To add to the complexity, IGF-I
treatment increased IGFBP-l concentrations by 6-8-fold in cultured fibroblast cells (Hill
et al., 1989) but decreased secretion in cultured rat hepatocytes (Scharf et aI., 1996) and
human endometrial cells (Clemmons et aI., 1990; Thrailkill et al., 1990). These results
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suggest that the specific effect ofIGF-I and -II on IGFBP-l production may be ceU type
dependent as previously suggested (Camacho-Hubneret aI., 1991).
EGF. Within the ovarian compartment, EGF enhances the mitogenic activity of
IGF-I in cultured granulosa (SaviOR et aI., 1981; May et aI.• 1988; Vernon and Spicer,
1994) and thecal ceUs (May et aI., 1992; Spicer and Stewart, 1996) but inhibits
steroidogenesis (Langhout et aI., 1991; Spicer and Stewart, 1996). In pigs and humans,
as follicle size increases, levels ofEGF-like activity decrease (Hsu et aI., 1987;
Westergaard et aI., 1990). From this work, it is postulated that EGF may be involved
with enhancing growth of small antral follicles as well as slowing the tenninal maturation
ofpreovuJatory follicles (Monniaux et aI., 1997). The action ofEGF on IGFBP-l
production remains in question, however. EGF increases IGFBP-l secretion in human
granulosa-luteal cells (Angervo et aI., 1992; Yap et aI., 1998), as well as human
hepatoma cells (Angervo, 1992) and endometrial cancer cells (Angervo et aI., 1991).
Similarly, when pigs are administered EGF for 4 weeks, serum IGFBP-llevels are
increased (Vinter-Jensen et aI., 1996). In contrast, 50 nglml and 10 nglml EGF had no
effect or reduced IGFBP-l concentrations in cultured human intestinal epithelial cells
(Oguchi et aI., 1993) and porcine aortic smooth muscle cells (Clemmons and Gardner,
1990), respectively. These results suggest that as with IGF-I, the specific effect ofEGF
on IGFBP-l production is dependent on cell-type. From the ovarian studies, one could
imply that the combination ofIGFBP-l and EGF may regulate follicular growth to
inhibit follicular atresia.
bFGF. Within the bovine ovary, bFGF is produced by the CL (Gospodarowicz et
aI., 1985; 1986; Stirling et aI., 1990; 1991) and granulosa cells (Neufeld et aI., 1987)
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while its receptors are found on ruminant thecal and granulosa cells (Wandji et aI., 1992;
DiBiasio et aI., 1993; Schams et aI., 1993). In addition, bFGF receptors and rnRNA
have been identified in bovine luteal cells (Stirling et aI., 1990, 1991) and human
granulosa cells (DiBlasio et aI., 1993). Like EGF, bFGF enhances granulosa cell
proliferation, but inhibits steroidogenesis in many mammals, including cattle
(Gospodarowicz and Bialecki, 1978, 1979; Gospodarowicz et aI., 1985;Wandji et aI.,
1992; Vernon and Spicer, 1994). Specifically, bFGF inhibits progesterone production in
pig (Channing et aI., 1983; Biswas et al., 1988), rat (Yamoto et aI., 1993) and bovine
thecal cells (Spicer and Stewart, 1996) and FSH-induced estrogen production in rat
(Baird and Hsueh, 1986; Adashi et aI., 1988a; Yamoto et aI., 1993) and bovine
granulosa cells (Vernon and Spicer, 1994).
Few studies have detailed the effects ofbFGF on the ovarian IGFBPs. In
cultured human granulosa cells, bFGF did not consistently alter IGFBP-l secretion (Yap
et aI., 1998). In porcine aortic smooth muscle cells, bFGF does not compete with IGF-I
for binding to IGFBP-1 (Clemmons and Gardner, 1990). Because bFGF is localized
within the ovarian compartments and is involved in inhibiting steroidogenesis, as
previously discussed, bFGF may playa pennissive role to enhance growth and delay
tenninal maturation of follicles (Monniaux et aI., 1997).
Gonadotropins
FSH. In humans, developing, preovulatory follicles progressively accumulate
FSH whereas atretic follicles diminish in FSH concentrations (McNatly et aI., 1975). In
cattle, a rise in systemic FSH preceeds a wave of follicular growth and selection ofa
dominant follicle (Ginther et al., 1996). Thus, follicles either die by atresia or are
--
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rescued by high concentrations ofFSH. Down- regulation of the IGFBPs, possibly
caused by high concentrations ofFSH, pennits IGF-I and FSH to synergize and promote
follicle growth and development. Conseqently, IGFBPs are generally not detected in
large estrogen-active follicles prior to the LH surge in cattle, excluding IGFBP-3
(Echtemkamp et a1., 1994a). In humans (Cataldo and Giudice, 1992a,b; Giudice et ai.,
1993; San Roman and Magoffin, 1993), rats (Erickson et aI., 1992a,b), and pigs (Grimes
et aI., 1994a; Howard and Ford, 1992), IGFBP-2, -4, and -5 have antigonadotropic
effects on ovarian stimulation by FSH. FSH, acting through the cAMP pathway, may
decrease IGFBP release and enhance the access of endogenously generated IGFs to their
cognate cell surface receptors and hence, cellular hormonal action. However, the effect
ofFSH on IGFBP-l production does not conclusively support the antigonadotropic
potential proposed. Mason et aI. (1993) demonstrated that 0.1-10 nglml FSH increased
IGFBP-l concentration by cultured human granulosa cells primarily from large (> 5 rom)
follicles (Mason et aI., 1993). Another study which contradicted Mason et aI. (1993),
demonstrated FSH (Ialkanen et a1., 1989; Ovesen et aI., 1994) or the combination ofGH
and FSH did not affect IGFBP-I production of human granulosa cells (Ovesen et a1.,
1994). However, the experiment did not include large preowlatory follicles, like the
study by Mason et aI. (1993). Finally, Adashi et aI. (1991) concluded that FSH affects,
in a biphasic manner, IGFBP-l production by rat granulosa cells. Low doses ofFSH
stimulated IGFBP-I whereas higher doses inhibited IGFBP-l production in vitro (Adashi
et aI., 1990a; Adashi et ai., 1991). The low dose ofFSH, used by Mason agreed with
these studies. Thus, these different results may be explained, in part, by the different size
of follicles used within each experiment or the different concentrations ofFSH applied.
--
LH. Pulsatile LH secretion plays an important role in follicular development in
cattle (Spicer and Echtemkamp, 1986; Ginther et aI., 1996), and acquisition ofLH
receptors in granulosa cells is a critical step in follicular development (Spicer and
Echterkamp, 1986; Ginther et aI., 1996; Stewart et aI., 1996; Baa et aI., 1997). How
LH and the IGF system regulate each other is still unclear. Stewart et aI. (1995)
demonstrated that IGF-I increases LH/hCG binding sites in bovine thecal cells, and
similar results are seen in rat granulosa cells (Adashi et aI., 1985; Davoren et aI., 1985;
1986). However, LH (10 nglml) or hCG (100 nglml) had no effect on IGFBP-I mRNA
or its protein by human thecal (Voutilainen et aI., 1996) or granulosa-luteal cells cultured
48 h (Ialkanen et al., 1989), respectively. Conversely, Giudice et aI. (1991) demonstrated
that IGFBP-l increased 6 to 8-fold with the addition of 10 nglml of hCG to human
luteinized granulosa cells cultured for 72 h. Higher doses (100 and 1000 nglml) ofhCG
did not as effectively impact IGFBP-l production (Giudice et aI., 1991). Studies
involving uterine stromal tissue have confirmed the stimulatory effect ofhCG on IGFBP-
I production (Tang et aI., 1993; Han et aI., 1995). These studies suggest IGFBP-l
production by granulosa cells is dependent on the dose and duration ofLH/hCG
treatment, and further substantiate an interactive association between LH and the ovarian
IGF system.
Steroids
Estradiol. Levels ofcirculating estradiol increase progressively with the growth
of the follicle and the increase in thecal and granulosa cell numbers. Once the critical
estradiol level is attained, it activates the release ofGnRH and consequently, LH. Thus,
the increase in estradiol is crucial for folliculogenis and ovulation. An increase in low
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molecular weight IGFBPs in bovine follicular fluid is associated with a loss of estrogenic
capacity by large non-ovulatory follicles before the preovulatory surge ofLH
(Echtemkamp et al., 1994a; Roberts and Echternkamp, 1995). Subsequent changes in
preovulatory follicular steroidogenesis following the preovulatory surge ofLH may be
independent ofIGF-I and/or IGFBP regulation, but loss ofestrogenic capacity by
dominant non-ovulatory follicles in cattle is associated with increases in IGFBP-2, -4,
and 5 levels (Funston et al., 1996~ Stewart et al., 1996). Estradiol inhibits IGFBP-l
protein and mRNA levels by human luteinizing granulosa cell cultures (Iwashita et aI.,
1994) and rat endometrial tissue (Molnar and Murphy, 1994), respectively. However, in
vivo work suggests that estrogen stimulates serum (Martikainen et at, 1992) and
endometrial (Fazleabas et aJ., 1989) IGFBP-l concentrations in human and non-human
primates, respectively. These studies suggest that IGFBP-I levels are regulated
differently between species and cell-type.
Cortisol. Glucocorticoids inhibit follicular function by inhibiting FSH-induced
aromatase activity in cultured rat granulosa cells (Hsueh and Erickson, 1978). Likewise,
glucocorticoids can inhibit somatic growth in humans by inhibiting GH and IGF-I activity
(Miell et aI., 1993~ 1994). However, in the cow, cortisol increases IGF-I-induced
granulosa and thecal cell numbers, and increase progesterone and androstenedione
production in thecal cells (Spicer and Chamberlain, 1998). Hence, there is evidence that
glucocorticoids may be involved directly in fo]]iculogenesis. Glucocorticoids may have
an essential role in hepatic IGFBP-l expression (Conover et at, 1993 a~ Lee et aI., 1993).
In vivo, dexamethasone decreased serum IGFBP-l in healthy human males (Miell et aI.,
1993; 1994). However, dexamethasone increased plasma IGFBP-Ilevels in rats (Luo et
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ai., 1990) and hullWlS (Conover et ai., 1993a). In vitro work using rat (Orlowski et aI.,
1990) and human (powell et aI., 1993) hepatoma cells supports the stimulatory action of
dexamethasone on IGFBP-l production. Reasons for the varied results among studies
are uncertain. Whether cortisol or other glucocorticoids affect ovarian IGFBP-l
production remains to be determined.
Metabolic HonnoDei
Qli GH receptors or its mRNA have been demonstrated in human (Tamura et
aI., 1994), bovine (Tanner and Hauser, 1989), and rat (Carlsson et ai., 1993) granulosa
cells. In the presence of insulin, GH stimulates granulosa cell growth in the cattle
(Langhout et ai., 1991) and swine (Hsu and Hammond, 1987). Likewise, GR stimulates
steroidogenesis in cultured rat (Iia et aI., 1986), human (Ovesen et aI., 1994), and
porcine (Hsu and Hammond, 1987; Samaras et aI., 1994) granulosa cells, and bovine
thecal cells (Spicer and Stewart, 1996). GH treatment alone or in combination with FSH
or estradiol stimulates IGF-I production by cultured porcine (Hsu and Hammond, 1987).
GH may aiso indirectly alter ovarian IGF action by modulating intrafollicular levels of the
IGFBPs (for review see, Rechler, 1993). Indeed, at 10 or 100 ng/ml in vivo and 0.1
mglkg in vitro, GH increased IGFBP-l levels in human follicular fluid (Rabinovici et ai.,
1997) and spent culture medium from granulosa cells (Ovensen et ai., 1994),
respectively. In contrast, GR (10 ng/ml) had no effect on cultured human thecal cell
IGFBP-l mRNA production (Voutilainen et al., 1996). This lack of effect corresponds
with the finding that human IGFBP-l mRNA was only found to be expressed in cultured
thecal cells not the thecal cell, per se. Similar to the thecal cells, no GR effect was
observed in cultured rat hepatocytes (Scharfet al., 1996). Upon injection afar
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immunization against GH, in postmenopausal women and (Kassem et aI., 1998) mice
(palmer et aI.1994), respectively, serum IGFBP-llevels decreased. Moreover, upon co-
administration ofbGH and the antiserum to GH, IGFBP-l serum levels were comparable
to the control group (palmer et aI., 1994). Thus, most studies support the stimulatory
action of GH on IGFBP-l protein levels.
Insulin. Insulin stimulates granulosa cell estradiol (Veldhuis and Furlanetto,
1985; Poretsky and Kalin, 1987; Maroo et aI., 1988; Caubo et aI., 1989; Urban et aI.,
1990; Spicer and Chamberlain, 1998) and thecal androgen (Caubo et aI., 1989; Morley et
aI., 1989; Stewart and Spicer, 1995) production in several species. Pigs, exogenously
administered insulin increases ovulation rate (Cox et aI., 1987) and decreases follicular
atresia (Matamoros et aI., 1990; 1991) whereas insulin increases follicular fluid estradiol
concentrations in superovulated cattle (Simpson et aI., 1994). Edwards et aI. (1996)
research demonstrated that absence of insulin reduced follicular growth and IGF-I levels
in the acute (6 days) diabetic pig. Thus, exogenous insulin positively affects
intrafollicular IGF-I (Meurer et aI., 1991; Cox et aI., 1994; Simpson et aI., 1994). The
absence of insulin during diabetes mellitus also altered the IGFBPs in cultured porcine
follicles in the presence of androgen substrate without affecting steroidogenesis
(Edwards et aI., 1996). Serum levels of insulin in healthy and diabetic subjects (Suikkari
et aI., 1988; Lee et al., 1993), as well as streptozocin-induced diabeteic pigs (Edwards et
aI., 1996) are inversely related to IGFBP-l concentrations. Insulin exerts an inhibitory
influence on IGFBP-l production at the transcriptional level (Orlowski et aI., 1991;
Powell et aI., 1991). Insulin also enhances the turnover rate ofIGFBP-l by stimulating
its mobility through the endothelium wall (Bar et aI., 1990a,b). In vitro, 25 or 250 ng/ml
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of insulin and 2 mglml of insulin-conditioned medium inhibited production of IGFBP-l
protein (Holst et al., 1997) and mRNA (Cataldo et aI., 1993), respectively, by human
granulosa cells. However, 1 or 10 nglml of insulin, which are within the physiologic
range (Diamond et aI., 1985), did not significantly reduce IGFBP-l production in
cultured human luteinized granulosa cells (poretsky et aI., 1996). Scharfet aI. (1996)
demonstrated that insulin decreased IGFBP-l concentrations in a dose-dependent
manner by cultured rat hepatocytes.
Glucagon. In contrast to insulin, glucagon stimulates glucose output within the
liver. Insulin primarily inhibits IGFBP secretion. Because ofthe opposing effect between
glucagon and insulin, one could speculate that IGFBP secretion would elevate in the
presence ofglucagon. Research involving human fetal liver explants (Lewitt and Baxter,
1989), and cultured rat liver cells (Kachra et aI., 1991; Denver and Nicoll, 1994) support
this concept. In one such study, healthy and GH deficient patients experienced an
increase in serum IGFBP-I when administered glucagon treatments (Hilding et aI.,
1993). Serum insulin and glucose were also increased, but decreased subsequent to the
IGFBP-l increase (Hilding et aI., 1993). The decrease by insulin would imply that at
physiological levels, glucagon has an overriding stimulatory effect thereby negating the
domination usually induced by insulin. This is further supported by the increases
observed with both IGFBP-l and insulin after food consumption (Gibson et aI., 1995).
Moreover, phosphorylation of IGFBP-1 is not changed with glucagon treatments. As
previously stated, IGFBP-I is highly phosphorylated upon secretion from the liver
(Westwood et aI., 1994). However, non- or less-phosphorylated fonns ofIGFBP-I
levels are also evident as demonstrated in the maternal circulation during pregnancy
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(Westwood et aI., 1994). This suggests hepatic posttranslational processing ofIGFBP-
1 is unaffected by hormonal treatments (Westwood et aI., 1995). In spite of the
numerous reports that confinn the increase in IGFBP-l with glucagon treatment, there
are cases that are in contrast with these studies. Others found no stimulating effect by
glucagon on IGFBP-l concentrations, as exemplified by cultured human hepatoma cells
(powell et aI., 1991) and primary rat hepatocytes (Villafuerte et aI., 1992). Jensen et al.
(1991) did not find a consistent.response by serum IGFBP-l concentrations with
glucagon administration. Reasons for the discrepancies among studies may be due to
differences in treatment conditions as well as cell types and species.
Honnonal Regulation of IGFBP-2
Growtb Factors
IQE IGF-II (30 ng/OO) inhibited IGFBP-2 production by 49% compared to the
controls in cultured human granulosa cells (Cataldo et aI., 1993). In addition, 30 nglml
of[Leu27]IGF-II, which binds to type II but not type I IGF receptors, (Beukers et aI.,
1991) decreased IGFBP-2 to 290.10 of controls in cultured human granulosa cells (Cataldo
et aI., 1993). However, 30 ng/ml IGF-I did not affect IGFBP-2 production (Cataldo et
aI., 1993). These results indicate that ovarian IGFBP-2 production may be mediated
through the IGF type n receptor (Cataldo et aI., 1993). However, few effects by the
type II receptor have been reported for IGFBP-2 in other cell types. In cultured vascular
smooth muscle cells, IGFBP-2 secretion remains relatively unchanged with IGF-I or-II
treatments (Boumer et aI., 1992; Cohick et aI., 1993), and IGF-I inhibited IGFBP-2
production by cultured rat hepatocytes (Scharf et aI., 1996).
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EGF. IGFBP-2 production was not effected by EGF in cultured porcine
granulosa cells (Mondschein et al., 1990), human intestinal epithelial cells (Oguchi et aI.,
1993) or vascular smooth muscle cells (Boumer et aI., 1992~ Cohick and Clemmons,
1993). However, IGFBP-2 mRNA production increased with the addition ofEGF to
cultured rabbit proximal tubular cells (Yap et aI., 1997). These results indicate EGF is
ineffective on influencing IGFBP-2 protein levels, but may influence IGFBP-2
transcription by some ceO types.
bFGF. IGFBP-2 production was not influenced by bFGF in cultured vascular
smooth muscle cells (Boumer et al., 1992; Cohick and Clemmons, 1993; Cohick et aI.,
1995). However, bFGF increased IGFBP-2 in a dose-dependent manner by human
cultured neuroblastoma cells (Babajko et aI., 1997).
Gonadotropins
FSH. IGFBP-2 release is inhibited by FSH (200 nglml) in cultured porcine
(Mondschein et at., 1990; Grimes et at., 1992) and rat (Bicsak et at., 1990) granulosa
cells. However, treatment with 100 nglml ofFSH had no significant effect on JGFBP-2
levels in human luteinizing granulosa cells (Cataldo et aI., 1993). These discrepancies
may stem from the different FSH concentrations utilized.
LH. hCG treatment ofweaned sows from 0-18 h decreased porcine follicular
fluid IGFBP-2 (Howard and Ford, 1992). In addition, from 18 to 24 h, follicular
IGFBP-2 levels remained low and then dramatically increased at 30-36 h post-hCG
(Howard and Ford, 1992). Therefore, it was not until sows approached ovulation that
IGFBP-2 levels began to increase (Howard and Ford, 1992). In contrast, LH inhibits
IGFBP-2 production by human granulosa cells (Giudice et aI., 1991; Cataldo et aI.,
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1993) and ovine thecal cells (Armstrong et ai., 1996). LH (10 nglOO) had no effect on
IGFBP-2 mRNA production by cultured human thecal cells (Voutilainen et aI., 1996).
When 100 nglOO ofhCG was applied for 2 days to cultured human luteinizing granulosa
cells, IGFBP-21evels decreased with hCG after 2 days; after 5 days the decrease was
more marked (Cataldo et ai., 1993). Another experiment was set up to determine that
hCG was, in fact, inhibiting synthesis ofIGFBP-2 (Cataldo et aI., 1993). Cultured
human granulosa cells were first treated with or without hCG for 2 days. After 2 days
the cells were then treated with or without cycloheximide, a protein synthesis inhibitor,
in the absence ofhCG (Cataldo et aI., 1993). IGFBP-2 levels which were increased by
cyclohexarnide treatment was likely due to the release of intracellular stores ofIGFBP-2
(Cataldo et aI., 1993). Cells treated with hCG and then cycloheximide released less
IGFBP-2 compared to untreated cells (Cataldo et al., 1993). This suggests that hCG
attenuates releasable intracellular stores and the hCG-stimulated decrease in IGFBP-2
release does not result from increased intracellular accumulation ofIGFBP-2 (Cataldo et
al., 1993).
Steroid.
Estradiol. Estradiol is stimulatory to rat theca-interstitial cell IGFBP-2 rnRNA
(Ricciarelli et aI., 1991) whereas, synthesis ofIGFBP-2 protein is inhibited by estradiol in
rat and pig granulosa cells (Adashi et al., 1990; Mondschein et al., 1990; Riciarelli et aI.,
1991). In normal healthy humans (San Roman and Magoffin, 1993), bovine
(Echtemkamp et al., 1994a; Funston et aI., 1996; Stewart et aI., 1996), ovine (Spicer ct
aI., 1995), and porcine (Howard and Ford, 1992) follicular fluid, IGFBP-2 tended to
decrease with increasing estradiol concentrations. Moreover, IGFBP-2 in follicular fluid,
-..
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as demonstrated in the pig, may be associated with differentiation during the transition
from follicular to luteal tissue (Howard and Ford, 1992).
Cortisol. Dexamethasone and hydrocortisone stimulate secretion ofIGFBP-2
protein and mRNA by cultured mouse pancreatic ~-ceUs (Katz et aI., 1997) and rabbit
proximal tubular cells (Yap et aI., 1997), respectively. However, dexamethasone
inhibited IGFBP-2 production in cultured porcine stromal vascular cells (Chen et aI.,
1995). Whether cortisol affects IGFBP-2 production by granulosa or thecal cells
remains to be determined.
Metabolic Hormones
QI:L GH may affect amount of IGFBP-2 in serum but not in follicular fluid
Administration of GH to prepurbertal gilts for 20 and 40 days decreased IGFBP-2 in
serum whereas follicular fluid IGFBP-2 activity was not affected (Samaras et aI., 1994).
Likewise, humans injected with 0.1 mg/kg Gll, had no significant effect on IGFBP-2 in
follicular fluid (Rabinovici et al., 1997). However in humans (Hardouin et aI., 1989;
Clemmons et aI., 1991; Blum et aI., 1993) and transgenic mice (Camacho-Hubner et al.,
1991) deficient in Gll, serum IGFBP-21evels were elevated, though short-tenn changes
in GH did not affect circulating levels ofIGFBP-2 (Jorgensen et aI., 1993). GH of cattle
was similar to the human and mouse where IGFBP-2 serum levels decreased and IGF-I
increased (Cohick and Clemmons, 1993; Stanko et al., 1994), but gene expression of
IGFBP-2 was not effected in the ovary (Kirby et aI., 1996). In heifers immunized against
GH-releasing honnone, which decreases serum GH and IGF-I, serum and follicular fluid
IGFBP-2levels are increased (Cohick et aI., 1996). IGFBP-2 production by human
luteinizing granulosa (Cataldo et aI., 1993) and IGFBP-2 mRNA in thecal cells
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(Voutilainen et al., 1996) and rat hepatocytes (Scharf et al., 1996) were not influenced
by GR treatment in vitro. These results indicate that GR treatment in vivo Qr in vitro, has
no effect on ovarian IGFBP-2 production.
Insulin. Although insulin stimulates IGFBP-2 production in cultured porcine
granulosa cells (Grimes and Hammond, 1992; Samaras et al., 1993) the effects of insulin
appeared to depend on insulin concentration. For example, ifrat intestinal epithelial cells
are cultured with low doses of insulin (1.0-5.0 ~glml), IGFBP-21evels increased whereas
high doses (10 J.1g1ml) decreased IGFBP-2 levels (Guo et aI., 1995). Similar results were
also reported in cultured rat hepatocytes (Scharfet aI., 1996). Although the lower dose
(5 J.1g1ml) increased IGFBP-2 protein levels in cultured rat intestinal epithelial cells,
IGFBP-2 mRNA was decreased (Guo et aI., 1995). The increase in IGFBP-2 secretion
therefore appears to be at a translational or posttranslationallevel whereas the decrease
in IGFBP-2 may be due to the dramatic reduction in IGFBP-2 mRNA expression (Guo
et al., 1995). Human serum IGFBP-2 levels remained unchanged during an overnight
fast or after ingestion ofa morning meal (Clemmons et al., 1991). These data indicate
that circulating IGFBP-2 is not altered by acute fluctuations in insulin at physiological
doses. However, Edwards et aI. (1996) demonstrated an increase in follicular fluid
IGFBP-2 levels in diabetes mellitus-induced pigs. Moreover, when human subjects are
fasted for 9 days, IGFBP-2 increases 1.7-fold (Clemmons et aI., 1991). So IGFBP-2
may be elevated in cases of extreme and/or long-tenn insulin deficiency, such as insulin-
dependent diabetes mellitus. IGFBP-2 levels, which can cross the endothelial barrier (Bar
et al., 1990a,b), may serve as a stable intennediate level ofcontcol in IGF action between
IGFBP-3 which does not cross the endothelial barrier and IGFBP-I, which undergoes
---
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acute, metabolically induced fluctuations. Therefore, chronic changes in insulin secretion
affect serum IGFBP-2, although adaptation to insulin is relatively slow (Bereket et aI.,
1995).
Glucagon. Few, ifany studies have analyzed the effects of glucagon on ovarian
IGFBP-2 concentrations. However, Denver and Nicoll (1994) investigated whether
glucagon effected IGFBP-2 levels by cultured rat hepatocytes. Although IGFBP-l levels
were increased, IGFBP-2 activity was not influenced by glucagon treatment (Denver and
Nicoll, 1994). Whether glucagon alters ovarian IGFBP-2 production remains to be
elucidated.
Hormonal Regulation of IGFBP-3
Growth Factors
IGF. IGF treatment has rather consistent effects on IGFBP-3 production among
the various cell types, IGF-I, IGF-II and [Leu21]IGF-1I all increased IGFBP-3 in
cultured human luteinized granulosa cells supplemented with insulin (Cataldo et al.,
1993), with insulin having no effect. Grimes and Hammond (1992) reported similar IGF
treatment effects on IGFBP-3 production by porcine granulosa cells. Outside the ovary,
IGF-I treatment increased IGFBP-3 mRNA by two- (Camacho-Hubner et aI., 1992), and
6-fold (Bale and Conover, 1992) in cultured human fibroblasts and bovine fibroblasts,
respectively, but had no effect on cultured human retinal pigment epithelial cells
(Feldman and Randolph, 1994). The increase in mRNA in human fibroblasts is similar to
the observed increase in IGFBP-3 protein level (Camacho-Hubner et ai" 1992). IGFBP-
3 production was also increased in cultured human keratinocytes, but its message
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decreased subsequent to IGF-I treatment (Wraight and Werther, 1995). The increase in
IGFBP-3, due to IGF-I, or -II, appears to be due to enhanced synthesis ofIGFBP-3
(Camacho-Hubner et aI., 1992). Moreover, because IGFBP-3 has a greater affinity for
IGF-I than the IGF-I receptor (McCusker et aI., 1990), the IGF peptides may act to
stimulate prefonned IGFBP-3 through a nonreceptor-mediated mechanism, possibly by
interaction with cell surface-adherent IGFBP-3 (Cataldo et ai., 1993). Release of
IGFBP-3 in bovine (McCusker et al., 1990) and human (Conover, 1991; Neely and
Rosenfeld, 1992) cultured fibroblasts have in fact been shown to be non-receptor
mediated.
EGF. The effect ofEGF on IGFBP-3 production is inconsistent across
experiments and cell type. Within the ovary, EGF did not effect IGFBP-3 production
levels by cultured porcine granulosa cells (Mondschein et aI., 1990). Likewise, EGF did
not significantly affect IGFBP-3 protein or mRNA by cultured human intestinal- (Oguchi
et ai., 1993) or retinal pigment-epithelial cells (Feldman and Randolph, 1994),
respectively. In contrast, EGF increases IGFBP-3 synthesis by cultured rat astroblasts
(Loret et aI., 1991) and human retinal pigment epithelial cells (Feldman and Randolph,
1994). Moreover, yet another cell line exhibited contradictory responses to the above
cell types. EGF treatments decreased IGFBP-3 protein and mRNA levels by cultured
human cervical epithelial cells (Andreatta-Van Leyen et aI., 1994) and keratinocytes
(Wraight and Werther, 1995) and mouse embryo fibroblasts (Villaudy et aI., 1991).
Vinter-Jensen et aI. (1996) likewise reported a decrease in serum IGFBP-3 levels in
goettingen minipigs administered EGF daily for 4 weeks. The conglomeration of results
would suggest, the IGFBP-3 response to EGF appears to vary with cell type/sample.
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bFGF. IGFBP-3 levels from cultured rat astroblasts decreased in response to
bFGF (Loret et aI., 1991). Like other honnone interactions previously discussed, the
variable results are likely due to the differences in cell types.
Goaadotropinl
FSH. FSH is generally inhibitory or without effect on ovarian IGFBP-3 levels.
For example, FSH inhibited IGFBP-3 production by cultured human granulosa cells from
polycystic ovarian foHicles (San Roman and Magoffin, 1992) as well as porcine
granulosa cells (Mondschein et aI., 1990; Grimes et aI., 1992). Likewise, administration
ofFSH to hypophysectomized rats, resulted in decreased IGFBP-3 mRNA in theca-
interstitial cells (Rohan et aI., 1993). However, IGFBP-3 levels from large follicles of
cyclic cattle were not influenced by exogenous administration ofFSH (Echternkamp et
aI., 1994a). Data from these experiments suggest the difference between species impact
the interaction between FSH and IGFBP-3.
LH. IGFBP-3 levels among preovulatory and nonovulatory follicles remained
relatively constant before and after the LH surge in cattle (Funston et aI., 1996).
Likewise, levels of serum IGFBP-3 are similar to follicular levels in cattle (Echtemkamp
et aI., 1994a; Funston et aI., 1996). However, ligand blots revealed porcine IGFBP-3 in
blood and follicular fluid decreased in a linear manner from 0 to 36 h after in vivo
treatments of 500 ill heG (Howard and Ford, 1992). In vitro work in cultured human
thecal (Voutilainen et aI., 1996) and granulosa cells (Giudice et al., 1991) indicated LH
and heG had no effect on IGFBP-3 mRNA, but decreased IGFBP-3 protein levels in
granulosa cells (San Roman and Magoffin, 1992). Therefore, the influence ofLH on
IGFBP-3 appears to be determined by type of cell and species.
r-
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Steroid.
Estradiol. Although the low molecular weight IGFBPs in foUicular fluid are
negatively correlated with estradiol concentration, IGFBP-3 levels are not effected.
Estrogen enhances IGFBP-3 mRNA in a dose-dependent manner in primary rat
osteoblast cultures (Schmid et aI., 1989), but has no effect on IGFBP-3 production by
porcine granulosa cells (Mondschein et aI., 1990). Likewise, estradiol did not effect
IGFBP-3 protein serum levels ofinfertile women undergoing in vitro fertilization
(SaIobir et aI., 1996) or in cultured human fibroblasts (Camacho-Hubner et aI., 1992).
However, exogenous administration ofestradiol to cattle resulted in an increase in
IGFBP-3 serum levels. These discrepancies may be due to a variety of influences such as
cell type, species differences, and variation in treatment.
Cortisol. Like many of the hormone treatments previously discussed, the
influence of cortisol on IGFBP-3 production by various cell types is inconsistent. Miell
et aI. (1993~ 1994) showed that dexamethasone in vivo increased IGF-I and IGFBP-3
levels in healthy males. In contrast, treatment of cultured human fibroblasts with
dexamethasone decreased IGFBP-3 production (Camacho-Hubner et at, 1992) but had
no effect on human keratinocytes (Wraight and Werther, 1995). IGFBP-3 mRNA levels
were likewise affected, exhibiting an inhibitory response to glucocorticoid treatment in
human osteoblast-like cells (Okazaki et al. 1994). Thus a possible post-translational
mechanism may affect IGFBP-3 production in osteoblast-like cells. However, due to the
differences in cell culture systems, the reason for IGFBP-3 regulation by cortisol is
inconclusive. Thus, whether cortisol affects ovarian IGFBP-3 is unknown.
~.
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Metabolic Hormooel
GH. Somatotropin appears to play an influential role in regulating circulating
IGFBP-3. Somatotropin treatments to lactating cows (Cohick et aI. 1993) and
postmenopausal women (Kassem et aI. 1998) increased serum IGFBP-3 levels.
Conversely, immunization of heifers against GH-releasing honnone decreased serum and
follicular fluid IGFBP-3 levels (Cohick et ai., 1996). Moreover, when Type 1 and 2
diabetic patients were administered insulin and octreotide, a somatostatin analogue,
serum levels ofIGFBP-3 decreased (Lunetta et al.,1997). As previously mentioned,
IGFBP-3 appears as two bands with approximate molecular weights between 40- and
45-kDa. These bands are barely visible in Laron-type (GH-deficient) patients
(Gourmelen et al., 1991). Similar stimulatory effects ofGH on IGFBP-3 protein and
mRNA have likewise been demonstrated in cultured human luteinizing granulosa cells
(San Roman and Magoffin, 1993) and rat theca-interstitial cells (Rohan et al., 1993). In
contrast, IGFBP-3 mRNA was not influenced by GH treatment in the day 17 bovine
uterus, ovary, or oviduct (Kirby et aI., 1996).,The discrepancy ofGH treatment on
IGFBP-3 mRNA could be due to the acquirement of mRNA on day 17 after estrus
(Kirby et aI. 1996), which could compromise GH effects because ofGH receptor down-
regulation. Moreover, Samaras et aI. (1992) found that porcine IGFBP-3 mRNA,
primarily found in the CL of the ovary, declined with luteal regression. Hence, the lack
of effect of GH on IGFBP-3 expression may also be due to a lack of expression of
IGFBP-3 on day 17 of the bovine estrous cycle (Kirby et al. 1996). From this
conglomeration of research, GH generally appears to stimulate the production of
IGFBP-3.
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Insulin. The effects of insulin on IGFBP-3 production are quite diverse between
the cell types. For instance, IGFBP-3 production was enhanced by treatment of cultured
porcine granulosa ceUs with insulin (Grimes and Hammond, 1992) but insulin had no.
effect on IGFBP-3 protein or mRNA by cultured human retinal pigment epithelial cells
(Feldman and Randolph, 1994). Similar responses were observed with IGFBP-3 levels
in cultured human fibroblasts (Camacho-Hubner et aI., 1992) and granulosa cells
(Cataldo et aI., 1993). However, serum IGFBP-3 levels were inhibited in streptozocin-
induced diabetic pigs (Edwards et al., 1996). These experiments suggest that the affect
ofinsulin on IGFBP-3 levels are influenced by different cell types and species.
Glucagon. Currently, no information is available regarding the effects of
glucagon on IGFBP-3 production. Whether glucagon alters ovarian IGFBP-3 is thus
unlmown.
Honnonal Regulation of IGFBP-4
Growth Factors
IGF. The influence of the IGFs on IGFBP-4 production varies with cell type.
IGFBP-4 concentrations increase with IGF-I treatments of cultured rat hepatocytes
(Scharf et aI., 1996) but are not affected in moderately differentiated cultured porcine
granulosa cells (Grimes et aI., 1994a). However, in cultured human fibroblasts (for
review see, Conover, 1996) and porcine vascular smooth muscle cells (Boumer et aI.,
1992; Cohick et aI., 1993), IGF decreases IGFBP-4 activity presumably by activating a
protease to cleave IGFBP-4 (see later section). Irwin et al. (1995) conducted a study in
which IGF-I or -II was incubated with IGFBP-4 in a serum-free conditioned medium.
r-
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Immunoblotting indicated that both IGF-I and -ll induced a rapid reduction in IGFBP-4
(24-kDa) levels but generated a 16-kDa IGFBP-4 fragment, suggesting direct activation
ofa protease by the IGFs (Irwin et a1., 1995). A similar inhibitory response ofIGF-ll and
IGFRP-4 was observed in cultured human pre-antral follicles (Yuan and Giudice, 1999).
Thus, the regulation ofIGFBP-4levels appears to be facilitated by the combination of
IGF Uld proteolytic activity.
EGF. Little work has demonstrated the effects ofEGF on IGFBP-4 production,
especially in ovarian cells. However, EGF stimulates IGFBP-4 protein and mRNA
secretion by cultured human intestinal epithelial cells (Oguchi et a1., 1993) and rabbit
proximal tubular cells (Yap et aI., 1997), respectively. In contrast, no effects by EGF
were observed on IGFBP-4 production by cultured human fibroblasts (Conover et a1.,
1993b). Differences in cell type would likely explain the discrepancies of these results.
bFGF. Little work has evaluated the effects ofbFGF on ovarian IGFBP-4. bFGF
increased IGFBP-4 production by skeletal cells (Chen et al., 1993) and by cultured
human neuroblastoma cells (Babajko et al., 1997) but inhibited production by glia ceUs
(pons and Torres-Aleman, 1992). Similar to Pons and Torres-Aleman (1992), Hurley et
aI. (1995) found that expression ofIGFBP-4 mRNA and its protein decreased in fetal rat
osteoblast cells (Hurley et al., 1995), suggesting the involvement of post-translational
mechanisms to regulate IGFBP-4 (Hurley et aI., 1995). However, Chen et a1. (1993),
found that bFGF did not regulate the IGFBP-4 mRNA in primary osteoblast-like cells
from fetal rat calvariae. These different outcomes of IGFBP-4 production from bFGF
treatments suggest that the discrepancies are due to the different cell models used.
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Gonadotropins
FSH. Cultures of rat granulosa cells with FSH for 24 h stimulated production of
IGFBP-4 (Adashi et aI., 1991~ Adashi et aI., 1993). Treatment with FSH., likewise
increased IGFBP-4 protein levels in moderately-differentiated porcine (4-6 nun)
granulosa cells whereas its message was not (Grimes et aI., 1994a). HUDWl pre-antral
follicles (Yuan and Giudice, 1999) and rat granulosa cells cultured 72 hours (Liu et aI.,
1993) in the presence ofFSH inhibited IGFBP-4 production. These contrasting results
may be explained by a biphasic effect on IGFBP-4 levels (Erickson et aI., 1994).
Erickson et al. (1994) demonstrated that low doses ofFSH (3 nglOO) increased IGFBP-4
production and high doses (30 and 100 nglml) inhibited IGFBP-4 accumulation by
cultured rat granulosa cells. Moreover, Western immunoblotting revealed new lower
molecular weight bands from the FSH-treated medium (Liu et aI., 1993). Unlike FSH-
free medium, a 21.5- and 17.5-kDa IGFBP, stained by IGFBP-4 antiserum resulted from
FSH treatment (Liu et aI., 1993). The 21.5-and 17.5-kDa could have derived from the
intact bands of28- and 24-kDa IGFBP, respectively, which were identified by
immunoblotting as IGFBP-4 in rat granulosa cells (Liu et aI., 1993). Moreover, 100
nglml FSH eliminated IGFBP-4 mRNA in cultured rat granulosa cells (Liu et aI., 1993).
This suggests that FSH may stimulate granulosa cell maturation by decreasing IGFBP-4
production and allowing the potentiating action of endogenously produced IGF-I.
LH. Addition of 10 ng/mJ of heG to cultured human luteinized granulosa celJs
increased IGFBP-4 6- to 8-fold when compared to the control (Giudice et a1., 1991).
Incubation of thecal cells with LH from both large and small ovine folJicles also enhanced
IGFBP-4 protein and mRNA production (Armstrong et a1., 1996; Armstrong et aJ.,
-43
1998). The thecal cell study further demonstrated a dose- and time-dependent
association ofLH treatment on IGFBP-4 enhancement (Armstrong et aI., 1996).
Steroid.
Estradiol. Estradiol has little effect on IGFBP-4 production. Estradiol had no
effect on IGFBP-4 production by cultured human fibroblast cells (Conover et aI., 1993b)
or porcine granulosa cells (Mondschein et aI., 1990). Likewise, exogenous
administration of estrogen did not effect the 22-kDa IGFBP (probably IGFBP-4) in
plasma of ovariectomized cattle. In contrast, exogenous administration of
diethylstilbestrol (DES) to hypophysectomized rats increased IGFBP-4 mRNA levels
(Ricciarelli et aI., 1991). The variability in these results suggests estradiol effects
IGFBP-4 gene expression rather than the protein per se.
Cortisol. Glucocorticoid treatment on IGFBP production results in a number of
variable effects by different cell types. For example, dexamethasone and hydrocortisone
stimulates IGFBP-4 protein and mRNA secretion by cultured mouse pancreatic J3-cells
(Katz et aI., 1997) and rabbit proximal tubular cells (Yap et al., 1997), respectively. In
contrast, both the protein and mRNA levels were decreased with the addition of
dexamethasone to cultured human osteoblast cells (Durham et aI., 1994b). However, in
cultured human fibroblast cells, Conover et al. (1993b) reported no change in IGFBP-4
production. This suggests that IGFBP-4 regulation is dependent upon cell type and
treatment utilized.
---
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Metabolic Hormones
GH. IGFBP-4 levels, in response to GR, are quite varied. GH (0.1 mglkg)
increased follicular fluid and serum IGFBP-4 levels in IVF women patients (Rabinovici et
al., 1997) and post-menopausal women (Kassem et aI., 1998), respectively, whereas
administration of porcine somatotropin (2-4 mg) per day for 6 weeks had no effect on
production of the porcine serum or follicular fluid 22-kDa IGFBP (probably IGFBP-4;
Echternakarnp et al., 1994b). Similarly, treatment with GH antiserum for 8 weeks had no
effect on rat IGFBP-4 serum levels (palmer et al., 1994), and immunization against GH-
releasing hormone, which decreases serum GH and IGF-I, has no effect on follicular
fluid IGFBP-4levels in heifers (Cohick et a1., 1996). However, co-administration ofGH
antiserum and bGH doubled rat serum IGFBP-4 levels (palmer et aI., 1994). Unlike
IGFBP-5, the increase in IGFBP-4 levels by GH treatment appears to be GH-
independent (Thoren et aI., 1998). However, in vitro studies have demonstrated that
IGFBP-4 production are not influenced by GH in human granulosa cells (Cataldo et a1.,
1992b), fibroblasts (Conover et a1., 1993b) and rat hepatocytes (Scharfet al., 1996), but
are stimulated in by GH in rat osteoblast-like cells (Chen et aI., 1991).
Insulin. To date, direct effects of insulin on IGFBP-4 production by ovarian cells
has not been documented. In cultured human fibroblast cells, Conover et aI. (1993b),
found no change to IGFBP-4 levels with insulin treatment whereas Camacho-Hubner et
a1. (1992) demonstrated that insulin enhanced IGFBP-4 production by 3.2-fold. Insulin
treatments of 10 ng/ml or less and 100 ng/ml did not affect IGFBP-4 production by
human endometrial stromal (Irwin et a1., 1995) and neuroblastoma (Babajko et al., 1997)
cells, respectively. However, insulin doses of 100 ng/m1 and 100 nmol/L applied to
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cultured human endometrial stromal cells (Irwin et aI., 1995) and rat hepatocytes (Scharf
et aI., 1996), respectively, accentuated IGFBP-4 concentrations. Similar studies using
cultured porcine vascular smooth muscle cells further support the increases in IGFBP-4
protein and mRNA observed with insulin treatments (Boumer et aI., 1992; Cohick et aI.,
1993).
Glucagon. Few studies have examined the effects ofglucagon on IGFBP-4
production. Research that has been perfonned resulted in no significant effect of
glucagon on IGFBP-4 production in cultured rat hepatocytes (Denver and Nicoll, 1994).
Hormonal Regulation ofIGFBP-5
Growth Factors
IQE Addition oflGF-1 to rat granulosa cell conditioned medium increased
IGFBP-5 production, and the effect was decreased with the addition ofFSH (Fielder et
aI., 1993). The combination oflGF-I (100 ng/ml) and FSH (100 ng/ml) to rat granulosa
cells also increased IGFBP-5 production, but with less of an effect than with IGF-I
alone. Similar findings with IGF-I were revealed in moderately differentiated porcine
granulosa cells from 4-6 nun follicles (Grimes et al., 1994a). Addition of2oo ng/ml of
FSH to porcine granulosa cells had no effect on IGFBP-5, but IGF-I-stimulated IGFBp·
5 production was decreased in porcine granulosa cells (Grimes et al., 1994a). Therefore,
IGF-I prevents the FSH-induced decrease in IGFBP-5 by rat granulosa cells (Fielder et
al., 1993).
In cultured human osteoblast cells, IGF-I and -II are the primary modulators of
IGFBP-5 (Conover and Kiefer, 1993). The effect ofIGF-I was dose dependent as
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demonstrated by a 2.6-fold increase in IGFBP-5 with 0.5 oM IGF-I and )O-fold increase
with 10 oM ofIGF-I (Conover and Kiefer, 1993). The effect ofIGF-I is also time-
dependent as demonstrated by the addition of 0.5 mM IGF-I which elicited a 3-fold
increase in IGFBP-5 at 2 h and a 10-fold increase at 24 h (Conover and Kiefer, 1993).
However, the increase in IGFBP-S levels by IGF-I did not reflect changes in IGFBP-S
mRNA expression (Conover and Kiefer, 1993). Similar findings of increased activity of
IGFBP-S, but not its message, due to the addition of and exposure to IGF-I were
revealed in cultured human fibroblast cells (Camacho-Hubner et aI., 1992). Thus,
IGFBP-5 appears to be posttranscriptionally regulated by IGF-I in cultured human
osteoblast (Conover and Kiefer, 1993) and fibroblast (Camacho-Hubner et aI., 1992)
cells. To increase IGFBP-5 in vitro, the protein must be associated with IGF-I and/or -
II, not the IGF receptor (Camacho-Hubner et aI., 1992). It is postulated that IGF-I
binds to secreted IGFBP-5, partially protecting it against hydrolysis by an IGFBP-5
protease (Conover and Kiefer, 1993; Nam et aI., 1994). Thus, in the absence ofIGF-I or
-II, IGFBP-5 undergoes proteolysis (for review see, Conover, 1996).
EGF. Few studies have involved EGF regulation ofthe IGFBPs. However, one
study has demonstrated that IGFBP-S mRNA production was decreased in the presence
ofEGF in cultured rabbit proximal tubular cells (Yap et aI., 1997).
bFGF. Like EGF, little ovarian work has detailed the influence ofbFGF with
IGFBP-5. However, both IGFBP-S and bFGF have prominent roles in bone cell
cultures. bFGF functions to stimulate bone cell replication (Canalis et aI., 1993; Canalis
and Gabbitas, 1995) while IGFBP-5 serves to enhance bone cell growth and stimulate
the anabolic actions ofIGF-I (Andress and Birnbaum, 1992). Treatment ofcultured fetal
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rat osteoblast cells with bFGF for 6 to 24 h diminished IGFBP-5 protein. as well as its
gene expression, and IGF-I activity (Canalis et aI., 1993; Canalis and Gabbitu. 1995).
Gonadotropins
FSH, Production ofIGFBP-5 by ovine cultured granulosa cells wu not affected
by FSH treatment (Monget et aI., 1998). However, in cultured rat granulosa cells, low
doses of ovine FSH (1-3 ng/m1) increased a 28-29 kDa IGFBP, representing IGFBP-5,
whereas high doses ofFSH (>10 ng/ml and 100 ng/ml; Adashi et aI., 1990a; Adashi et
al" 1991; Fielder et a1., 1993) inhibited IGFBP-5. Another lower molecular weight
IGFBP (21.0-kDa) was detected by Western immunoblots from granulosa cells with
FSH-treated medium which could be derived from the intact 29-kDa band ofIGFBP-5
(Liu et aI., 1993). Northern blot analysis also revealed that 100 ng/ml ofFSH decreased
IGFBP-5 mRNA in cultured rat granulosa cells (Liu et al., 1993). This suggests that
FSH works at the gene level to inhibit IGFBP-5 transcription or potentiate degradation
ofIGFBP-5 mRNA (Liu et al., 1993).
LH" Thecal and granulosa cell LH/hCG receptor numbers increase in the early
dominant follicle during the bovine estrous cycle (Xu et al., 1995b; Bodensteiner et aI.,
1996). Because bovine follicular fluid IGFBP-5 levels are negatively correlated with the
number of thecal LHlhCG binding sites, a regulatory role ofLH by IGFBP-5, as well as
IGFBP-2, and -4, is possible (Stewart et aI., 1996). However, another study found that
LH increased IGFBP-5 mRNA production by cultured human thecal cells (Voutilainen et
aI., 1996). Although these results are conflicting, the data supports the concept that
gonadotropins may regulate IGFBP-5 production in thecal tissue.
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Steroids
Estradiol. Although few studies have detennined the effects ofestradiol on
IGFBP-5 levels follicular fluid, a relationship between these two factors seems to exist.
Stewart et al. (1996) demonstrated that estradiol concentrations were negatively
correlated with IGFBP-5 concentrations in dominant and large bovine follicles. Similar
results were found in estrogen-active preowlatory follicles ofwomen (Schuller et ai,
1993). However, treatment of human cultured osteoblast cells with estradiol (100 nM)
had no effect on IGFBP-5 production (Conover and Kiefer, 1993). This discrepancy is
likely due to the cell-type studied within each experiment.
Cortisol. Glucocorticoids attenuate DNA and collagen synthesis in bone cultures
and decrease IGF-I synthesis in osteoblasts (McCarthy et al., 1990; Delany et al., 1994;
Okazaki et aI., 1994), so an interaction between IGFBP-5, a predominant IGFBP in
bone, and cortisol seems logical Treatment of cortisol decreased IGFBP-5 production in
the extracellular matrix of cultured fetal rat osteoblast cells (Gabbitas et al., 1996).
IGFBP-5 mRNA levels were also decreased in a time- and dose-dependent manner by
cortisol treatments which would suggest IGFBP-5 in fetal rat cultured osteoblast cells is
regulated transcriptionally by cortisol (Gabbitas et aI., 1996). Similar studies using
cultured human fibroblasts (Camacho-Hubner et aI., 1992) and osteoblast cells (Conover
and Kiefer, 1993) showed that dexamethasone treatments decreased or had no effect on
IGFBP-5 levels, respectively. Moreover, hydrocortisone increased IGFBP-5 mRNA by
,
rabbit proximal tubular cells (Yap et al., 1997). Therefore, species and/or cell-type likely
influences whether IGFBP-5 production is altered by glucocorticoids.
--
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Metabolic HormoDei
QK Immunization of cattle against GH-releasing honnone, which decreases
serum GH and IGF-I, has no effect on follicular fluid IGFBP-5 levels (Cohic~ et aI.,
1996). A study conducted by Thoren et aI. (1998) illustrated that serum IGFBP-5 levels
were significantly diminished in GH-deficient patients when compared to control
patients. Upon 36 months ofGH-therapy, serum IGFBP-51evels increased by 2-fold
after the third month oftreatment with the GH-deficient subjects (Thoren et aI., 1998).
However, IGF-I levels were also elevated which suggest that the increase in IGFBP-S is
not due to GH but IGF-I (Thoren et aJ., 1998). In support of this suggestion, no change
was detected in IGFBP-S protein levels with GH treatment (1 J.1g1m1) to human
osteoblast cells in vitro (Conover and Kiefer, 1993). However, GH increased IGFBP-S
mRNA levels in cultured fetal rat osteoblast cells (McCarthy et aI., 1994).
Insulin. The effect of insulin on IGFBP-5 production was determined because
insulin can bind to the IGF-I receptor, and IGF-I and -II significantly enhance IGFBP-5
activity in human fibroblasts (Camacho-Hubner et aI., 1992). However, treatment with
insulin to cultured human fibroblasts (Camacho-Hubner et aI., 1992) and osteoblast cells
(Conover and Kiefer, 1993) resulted in no significant effect on IGFBP-5 levels. These
results indicate that IGF-I and -II must associate with IGFBP-5 to increase IGFBP-5,
and that receptor binding is not required (Camacho-Hubner et aI., 1992).
Glucagon. Currently, no information is available regarding the effect ofglucagon
on IGFBP-5 production.
....
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Hormonal Regulation of IGFBP-6
Growtla Fadon
IGF. IGFBP-6, which binds IGF-II with ;20-100 times greater affinity than IGF-
I, selectively prevents the effects ofIGF-ll on myoblasts and osteoblasts (Kiefer et aI.,
1992; Bach et al., 1993; 1994). However, IGF-II had no effect on IGFBP-6 gene
expression by fetal rat osteoblast cells (Gabbitas and Canalis, 1997). Likewise, IGF-I had
no effect on IGFBP-6 mRNA expression in cultured fetal rat osteoblast cells (Gabbitas
and Canalis, 1997) or human retinal pigment epithelial cells (Feldman and Randolph,
1994). The lack ofeffect ofIGF on mRNA would suggest IGFBP-6 is not regulated by
transcriptional mechanisms. However, the modulation ofIGF-I1 by IGFBP-6 suggests
that changes in IGFBP-6 have the capability to alter the available levels ofIGF-II in
skeletal muscle and other tissues where both are produced (i.e., ovary).
EGF. Similar to the lack of effect ofIGF-II on IGFBP-6 production, EGF had
no effect on IGFBP-6 mRNA expression, but slightly increased IGFBP-6 protein levels
in cultured human retinal pigment epithelial cells (Feldman and Randolph, 1994). Thus,
within this cell-line EGF may have a minor role in the regulation of IGFBP-6. Whether
EGF plays a role in the regulation of ovarian IGFBP-6 is unknown.
bFGF. Unlike IGFBP-l to 5, bFGF had little effect on IGFBP-6 activity. For
example, IGFBP-6 mRNA and protein concentrations were not affected by treatment of
bFGF in reports using fetal rat osteoblast (Gabbitas and Canalis, 1997) or cultured
human neuroblastoma (Babajko et al., 1997) cells. Thus, from these few studies, bFGF
doesn't appear to regulate IGFBP-6 production. Whether bFGF alters ovarian IGFBP-6
production remains to be determined.
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Gonadotropins
FSH. Generally, granulosa cell-derived IGFBPs are reduced by FSH (Adashi et
aI., 199Oa). When hypophysectomized rats were treated with FSH, whole ovarian
IGFBP-6 transcripts decreased by 2.4-fold relative to that in hypophysectomized
controls (Rohan et aI., 1993). However, unlike most mammalian species, the
antigonadotropic potential of rat IGFBP-6 mRNA primarily works at the level of the
thecal cells rather than the granulosa cells (Rohan et al., 1993). Increasing concentrations
ofrhIGFBP-6 did not inhibit the FSH-supported accumulation of either progesterone or
estradiol by rat granulosa cells (Rohan et aI., 1993). This suggests that the failure of
rhIGFBP-6 to diminish FSH action by granulosa cells is due to its comparatively reduced
affinity for IGF-I (Kiefer et aI., 1992).
Steroids
Estradiol. Rat IGFBP-6 gene expression is primarily within the theca-interstitial
cells, with little or no expression in granulosa cells (Rohan et aI., 1993). Evidence
suggests estradiol inhibits IGFBP-6 production by ovarian cells. Administration ofDES
to hypophysectomized rats resulted in a 2.6..fold decrease in IGFBP-6 transcripts (Rohan
et aI., 1993). Because IGFBP-6 mRNA in rat theca-interstitial cells was inhibited by
estrogen (Ricciarelli et aI., 1992; Rohan et aI., 1993), estrogen's effect may be through a
direct influence on theca-interstitial cells (Rohan et aI., 1993). However, estrogen may
also effect IGFBP-6 transcript levels through a granulosa cell-derived intermediate
(Rohan et aI., 1993). Because FSH and estrogen enhance many rat granulosa cell
functions (Richards and Hedin, 1988), the latter idea is further supported by results
S2
which show the combination ofFSH and DES synergistically decrease the amounts of
whole ovarian IGFBP-6 transcripts (Rohan et aI., 1993).
Cortisol. Currently, no information is available regarding the effects of cortisol
on the production ofIGFBP-6.
Metabolic Hormones
QR. Treatment ofhypophysectomized rats with GH had no effect on IGFBP-6
mRNA levels in theca-interstitial cells (Rohan et al., 1993) or on systemic IGFBP-6
levels (Lee et al., 1997). GH treatment offetal rat osteoblast cells in vitro also had no
effect on IGFBP-6 mRNA (McCarthy et al., 1994).
Insulin. Unlike the other IGFBPs, IGFBP-6 is not impacted by insulin
treatments. As exemplified in cultured human retinal pigment epithelial (Feldman and
Randolph, 1994) and neuroblastoma cells (Babajko et aI., 1997), insulin had no effect on
IGFBP-6 mRNA Of protein levels, respectively. Thus, as indicated at least from these
cell culture types, insulin does not regulate the production ofIGFBP-6. The effect on
ovarian cells has not been determined.
Glucagon. Currently, no infonnation regarding the effect ofglucagon on IGFBP-
6 production is available.
Proteolysis of the IGFBPs
Posttranslational modifications decrease binding protein affinity for their peptide
ligands. As previously alluded to, proteolytic activity is one such mechanism that may
modulate the levels oflGFBPs within various tissues. Proteolysis of the IGFBPs was
originally described in the circulation of pregnant women (Giudice et aI., 1990a;
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Hossenlopp et ai., 1990). However, subsequent work has shown that modified or
cleaved binding proteins are present in most, if not ail extracirculatory fluids (Lalou and
Binoux 1993; Dodd et al., 1995; Xu et ai., 1995a; Matsumoto et aI., 1996). A prime
example ofIGFBP proteolysis can be found in the sheep ovary. In ovine follicular fluid,
proteases are produced for IGFBP-4, and to an extent for IGFBP-2, -3, and -S (Monget
et aI., 1996). During tenninal follicular growth of antral follicles, proteolytic activity of
IGFBP-3 is reduced while proteolysis ofIGFBP-2, -3, and -5 is enhanced (Monget et ai.,
1996). During atresia, IGFBP-3 proteolytic activity in small (2-3 rnm) ovine follicles
increases whereas IGFBP-4 and -5 proteolytic activity in large (>5 mm) follicles
decrease (Monget et aI., 1996).
Proteolysis of the IGFBPs is believed to modulate IGF bioavailability.
Theoretically, by cleaving the intact IGFBPs into fragments, the resulting degradation
could release bound IGF from the binding proteins, thus leading to follicular growth and
maturation (Grimes and Hammond, 1994). The majority of these proteolytic fragments
of the various IGFBPs do not bind IGF-I (Rajaram et aI., 1997). Conversely, a decrease
in IGFBP degradation could stabilize extracellular IGFs and fine tune IGF activity as
suggested by Grimes and Hammond (1994).
As mentioned earlier, IGF-I may stimulate IGFBP proteolysis. Iwashita and
colleagues (1996) suggested three possible mechanisms by which IGFs induce
proteolysis. These include either direct activation of a latent protease by IGFs, increased
susceptibility ofIGF/lGFBP complexes to proteolytic degradation and/or repression of a
protease inhibitor by the IGFs. Which, if any, theory is correct, is yet to be determined.
However one postulated theory about increasing the availability of the IGFs involves the
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interaction ofIGFBP-3 and the low molecular weight binding proteins (for review see,
Rajaram et al., 1997). Most IGFs are complexed to IGFBP-3 in the serum. An IGFBP-3
protease present in serum or vascular endothelial cells can cleave IGFBP-3 and therefore
release IGF. As previously mentioned, the binding ofIGF-I to IGFBP-3 increases the
half-life ofIGF-I from 20-30 minutes in the free form to approximately 15-20 hours in
the bound form (Zapfet aI., 1986). Once the IGFs dissociate from IGFBP-3, they either
remain free, or most likely, bind to a lower molecular weight IGFBP and cross the
endothelium. Once IGF is transported into the tissue space, a protease may degrade the
low molecular weight IGFBP, thus releasing and enabling IGF-I and -II to bind to their
receptors. Therefore, the IGFBP protease may modulate the transport ofIGFs into
tissue space, regulate the availability offree IGFs and alter the metabolic clearance rate
ofIGFs. However, proteolysis can not fully explain how IGF passes the endothelial
barrier since intact IGFBP-3 has been found in the follicular compartments. An
alternative hypothesis suggests that during preovulatory maturation, intrafollicular
IGFBP-3 activity is increased because of increased vascularization and perrniability of
the follicle during follicular growth, the entrance of serum-derived IGFs and IGFBPs
may ensue (Grimes et aI., 1994).
IGFBP-2 Proteolysis
Although little infonnation regarding IGFBP-2 proteolysis is available, indirect
evidence oflGFBP-2 protease activity has been demonstrated in bovine (Stanko et aI.,
1994), ovine (Besnard et aI., 1996b) and porcine (Besnard et aI., 1997) follicular fluid,
human thecaI- and stromal-conditioned medium (Mason et aI., 1996) and porcine smooth
muscle ceHs (Cohick et aI., 1995). Stanko et al. (1994) reported that in bovine follicular
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fluid of dominant and subordinate follicles, two non-IGF binding IGFBP-2 fragments,
approximately 22- and 14-kDa, existed along with the intact IGFBP-2 (34-kDa).
Similarly, Mason et aI. (1996) reported and intact IGFBP-2 band at 3S-kDa as well as
several lower molecular mass bands at 33-, 32-, 25-, 23-, 20.5-, and 16-kDa, detected by
immunoblotting, in human thecal- and stromal-conditioned medium. These bands were
postulated to be proteolytically cleaved products (Mason et aI., 1996).
Besnard et aI. (1996b) found that ovine follicular fluid from different classes of
follicles, likewise contained specific proteolytic activity degrading IGFBP-2. Indeed,
ovine follicular growth (between 2-6 nun) was characterized by an increase in IGFBP-2
proteolytic activity, as detected by immunoblotting (Besnard et aI., 1996b). Specifically,
IGFBP-2 proteolysis was slightly greater in medium sized follicles than in small follicles
(Besnard et al., 1996b). However, proteolytic activity in ovine medium follicles was
similar in atretic and healthy follicles (Besnard et aI., 1996b). Although IGFBP-2
proteolysis was detected in ovine follicles, IGFBP-3 and -4 are the predominant IGFBPs
undergoing proteolysis (both IGFBP-2 and -5 are degraded to a lesser extent) in the
sheep (Besnard et aI., 1996b). Thus, few studies have attempted to specifically identify
the IGFBP-2 protease in ovine follides.
Immunoblot analyses indicated an increase in a 22- and 14-kDa non-IGF binding
IGFBP-2 fragment as well as a decrease of intact IGFBP-2 in porcine smooth muscle
cells subsequent to IGF-II treatment (Cohick et aI., 1995). Treatment with IGF-I also
increased the appearance of the IGFBP-2 fragments, but a corresponding decrease of
intact IGFBP-2 did not result (Cohick et aI., 1995). In contrast, insulin treatment had no
effect on IGFBP-2 fragmentation by porcine smooth muscle cells (Cohick et aI., 1995).
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In addition, porcine follicular fluid from growing follicles 2-7 nun in diameter contained
proteolytic activity for IGFBP-2 whereas atretic follicles were associated with a marked
decrease in IGFBP-2 proteolytic activity (Besnard et aI., 1997). Indeed, incubation of
IGFBP-2 with porcine preowlatory follicular fluid resulted in the appearance ofa 16-
kDa fragment as detected by immunoblotting (Besnard et aI., 1997). However,
inhibition ofIGFBP-2 proteolysis resulted with the addition ofEDTA (calcium chelator)
or 1,10 phenanthroline (chelator of zinc ions) in porcine follicular fluid from
preowlatory follides (Besnard et aI., 1997). The addition of calcium chloride and zinc
chloride was necessary to completely restore IGFBP-2 proteolytic activity inhibited by
EDTA (Besnard et aI., 1997). PMSF (serine protease inhibitor), aprotinin (serine
protease inhibitor), benzamide (serine protease inhibitor), E64 (cysteine protease
inhibitor), phoshoramidon (endopeptidase inhibitor), and leupeptin (trypsin-like serine
and cysteine protease inhibitor) resulted in little to no inhibition of porcine IGFBP-2
proteolytic inhibition (Besnard et aI., 1997). These results indicate that the protease(s)
involved in the degradation ofIGFBP-2 in porcine follicular fluid belong to the
metalloprotease family and are zinc- and calcium-dependent (Besnard et aI., 1997).
IGFBP-3 Proteolysis
IGFBP-3 protease activity has been found in a variety ofbiological fluids,
including ovine follicular fluid and human (Giudice et aI., 1990b; Hossenlopp et aI.,
1990; Davies et aI., 1991), pig (Besnard et aI., 1997), sheep (Besnard et aI., 1996b), rat
(Davenport et aI., 1990; Gargosky et aI., 1990), and mouse (Fielder et at., 1990)
pregnancy serum, as well as the human prostate (Cohen et aI., 1992) and porcine
granulosa cells (Grimes and Hanunond, 1994). Furthermore, after the second month of
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pregnancy in humans, a significant decrease in binding protein activity, particular IGFBP-
3, has been observed. This decrease may be due to a serum protease which degrades
IGFBP-3 into fragments, releasing sequestered IGF for biological activity. When IGFBP-
3 undergoes proteolysis, low molecular weight fragments, detected by Western
immunOOlots, appear; these fragments do not bind IGF-I or -IT. In cultured human
thecal explants from dominant follicles, intact IGFBP-3 (41.5- and 44-leDa) as weD as a
lower molecular weight doublet (30- and 32-kDa) were detected by irnmunoblotting
(Cwyfan-Hughes et aI., 1997). The proportion ofIGFBP-3 appearing as a 30- and 32-
kDa doublet increased from 2 to 78% as the size of the dominant follicle increased
(Cwyfan-Hughes et aI., 1997).
Protease activity degrading IGFBP-3 was demonstrated in ovine follicular fluid,
primarily from small atretic follicles (Besnard et aI., 1996b). Degradation of ovine
follicular fluid IGFBP-3 was blocked by EDTA and 1,10 phenanthroline. However,
EDTA's effects was partially reversed by the addition of calcium chloride and completely
opposed by the addition ofboth calcium and zinc chloride whereas the effects of 1, I0
phenanthroline was negated with the addition of zinc chloride (Besnard et aI., 1996b).
These results suggest that intrafollicular ovine IGFBP-3 proteolytic activity, similar to
that ofIGFBP-2 in pigs, involves calcium- and zinc-dependent metaJloproteases
(Besnard et al., 1996b).
Porcine follicular fluid contains small amounts of proteolytic activity specific for
IGFBP-3 (Besnard et aI., 1997). Grimes and Hammond (1994) demonstrated that the
protease appears to be a soluble serine-specific protease, similar to plasmin, produced by
porcine granulosa cells. When cultured porcine granulosa cells were treated with 20
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~gIrnl aprotinin, a serine protease inhibitor, 1000.10 rhIGFBP-3 (29-kDa) remained intact
(Grimes and Hammond, 1994). In contrast, the addition of the cysteine-specific inhibitor
trans-epoxy succinly-L-Ieucyl-amido-(4-guanidino) butane, aspartic-specific inhibitor
pepstatin, or the metalloprotein-specific inhibitor 1, 10-phenanthroline, did not maintain
intact IGFBP-3 (Grimes and Hammond, 1994). Furthermore, plasmin and plasminogen,
an inactive precursor to plasmin, degrades rhIGFBP-3 into non-IGF-I binding fragments
ofapproximately 14.3-, 18.5-,22.5-, and 24-kDa. (Grimes and Hammond, 1994).
Similarly, plasmin has been shown to degrade IGFBP-l in osteoblast cultures (Campbell
et aI., 1992).
Regulation ofIGFBP-3 proteolysis is still in question, but is believed to be
hormonally controlled. Bang and colleagues (1994) demonstrated that insulin may be
involved in regulating IGFBP-3 proteolysis. In non-insulin dependent diabetes mellitus
patients that were administered insulin, IGFBP-3 protease activity decreased (Bang et
aI., 1994). Furthermore, Vinter-Jensen et al. (1996) hypothesized that because EGF
stimulates IGF-I biosynthesis in the liver (Barreca et al., 1992), systemic EGF affects the
post-transcriptional processing of the IGFfIGFBP-3 complex by inducing proteolytic
activity. However, Western immunoblots revealed that insulin (40% intact rhIGFBP-3)
or EGF (26% intact rhIGFBP-3) treatments had no significant effect on rhIGFBP-3
proteolysis, when compared to the controls (37% intact rhIGFBP-3) in cultured porcine
granulosa cells (Grimes and Hammond, 1994). Likewise, FSH (29%), estradiol (20%),
and GH (23%) did not significantly effect proteolysis (Grimes and Hammond, 1994).
Unlike the aforementioned hormones used by Grimes and Hammond (1994), the addition
ofIGF-I or -II to the porcine granulosa cell cultures, diminished proteolysis ofrhIGFBP-
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3 (Grimes and Hanunond, 1994). Addition ofgenistein, a tyrosine kinase inhibitor that
blocks the action of the type I receptor, can counteract IGF-I, as well as insulin
stimulation ofendogenous porcine IGFBP-3 production (Grimes and Hammond, 1994).
However, administration ofgenestein to the porcine granulosa cell cultures did not block
the IGF-I-induced inhibition of the degradation ofrhIGFBP-3 (Grimes and Hammond,
1994). Moreover, because insulin was ineffective in preventing degradation of
rhIGFBP-3, the insulin receptor is also an unlikely candidate to modulate protease
activity (Grimes et al., 1994). The type II receptor is also improbable because IGF
action within the porcine ovary appears to be through the type I receptors (Adashi et aI.,
199Ob~ Nissley and Lopaczynski, 1991). Because of these factors, a non-receptor-
mediated action to regulate IGFBP proteases of the IGFs must be considered. One
possibility of IGF action is the stabilization of IGFBP-3 from proteolysis by binding to
IGFBP-3.
IGFBP-4 Proteolysis
IGFBP-4 protease activity has been reported in porcine (Cohick et aI., 1993) and
human (Kamyar et aI., 1994) smooth muscle cells, human osteoblast-like cells (Durham
et aI., 1994a), fibroblasts (Fowlkes and Freemark, 1992~ Conover et aI., 1993b),
endometrial stromal cells (Irwin et at., 1995),.decidua (Myers et al., 1993), and dominant
estrogenic follicles (Chandrasekher et aI., 1995), rat neuronal cell lines (Cheung et aI.,
1994) and granulosa cells (Erickson et aI., 1994), porcine (Besnard et aI., 1997) and
ovine follicular fluid (Besnard et at., 1996b; Mazerbourg et aI., 1999), and both human
and ovine fibroblasts (Conover et aI., 1993b; Neely and Rosenfeld, 1992; Fowlkes and
Freemark, 1992). Binding of the IGFs to IGFBP-4 increases the susceptibility of this
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binding protein to proteolysis, possibly as the result of a conformational change (Mohan
et aI., 1994).
Similar to porcine IGFBP-2, a protease degrading IGFBP-4 from porcine
follicular fluid exists in growing follicles 2 nun and 6-7 rnm in diameter (Besnard et aI.,
1997). However, the addition ofEDTA and 1,10 phenanthroline to porcine follicular
fluid samples inhibits degradation ofIGFBP-4 (Besnard et aI., 1997). Likewise, in
porcine smooth muscle cells, an intact 24-kDa IGFBP, coinciding with nonglycosylated
IGFBP-4 is proteolytically cleaved to a 16-kDa fragment that is not capable ofbinding
IGF-I/-II (Cohick et aI., 1993). Exposure of these cells to IGF-I further increases the
amount ofIGFBP-4 fragments whereas exposure to insulin has no effect on IGFBP-4
proteolysis (Cohick et al., 1993).
Degradation ofIGFBP-4 in ovine follicular fluid is the primary IGFBP
undergoing proteolysis in preovulatory follicles (Besnard et al., 1996b). Degradation of
IGFBP-4 was completely blocked by chelating agents (EDTA and 1,10 phenanthroline;
Besnard et al., 1996b). Moreover, the addition of calcium chloride and/or zinc chloride
overrode the inhibition by the chelating agents, resulting in degradation of ovine IGFBP-
4 (Besnard et aI., 1996b). Thus, similar to the foHicular fluid protease found to degrade
IGFBP-2 and -3 in sheep and pigs, the IGFBP-4 protease is a caJcium- and zinc-
dependent metalloprotease.
In human fibroblasts and human osteoblast-like cells, the cleavage site of IGFBP-
4 is located in domain 2, which is the central nonconserved region of the binding proteins
(Conover et aI., 1995). The conserved domains 1 and 3, which are the NH2 and COOH-
tenninal portions of the binding proteins are important for IGF binding (Conover et aI.,
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1995). Therefore, the nonconserved domain 2 could be involved in regulating the
activity and lor tissue specificity of each IGFBP (Conover et ai., 1995).
Conover et al. (1993b), demonstrated that human fibroblasts secrete and IGFBP-
4 specific protease that is dependent upon IGFs for activation. Research has shown that
agents that complex divalent cations block the IGF-induced decrease in IGFBP-4
(Conover et al., 1993b). Furthermore, the protease involved in degrading IGFBP-4 is
specific for that protein. Conover et aI. (l993b) reported that cell-free incubation with
or without IGF-II had no effect on other binding proteins present in human fibroblast
conditioned medium or on IGFBP-1, -2, -3, -5, or -6, when added to the conditioned
medium. Therefore, the IGFBP-4 protease is unlikely to be the same as the cation-
dependent IGFBP-3 protease. Although the identity of the protease for IGFBP-4
remains unknown, IGFBP-4 protease levels are reduced in the presence of the
metalloserine protease inhibitor, EDTA (a divalent cation chelator), the serine protease
inhibitor aprotinin, and the metal ion chelator 1,10 phenanthroline, in human endometrial
stromal cells (Irwin et al., 1995) and human follicular fluid (Chandrasekher et al., 1995).
Other proteinase inhibitors including leupeptin, E64, ultrypsin inhibitor, pepstatin and
chymostatin were ineffective at inhibiting protease activity in human endometrial stromal
cells (Irwin et al., 1995).
Conover et al. (1995) suggested a role for kallikrein in the degradation of
IGFBP-4. These researchers demonstrated that the IGFBP-4 protease cleaves the intact
IGFBP-4 molecule at a single site on the carboxyl terminal side of methionine 135,
producing two fragments (18- and 14-kDa). the 14-kDa product is a result of cleavage
between methionine and lysine IGFBP-4. Consequently, tissue kallikreins are known to
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cleave peptide bonds between methionine and lysine and also between arginine and serine
in kininogen to release lyslybradykinin. Therefore, IGFBP-4 cleavage may be a result of
a hydrolytic enzyme with a specificity similar to that of kallikrein.
Chandresekher et al. (1995) demonstrated that IGFBP-4 protease activity in
human follicular fluid was pH and temperature dependent. A temperature range of 25-
37°C, but not 4°C, will induce protease activity, with maximal IGFBP-4 reduction
occurring at 37°C (Chandrasekher et aI., 1995). Likewise, optimal protease activity
ensues at a pH range of 7-9, but not 4-5 (Chandrasekher et aI., 1995).
An IGFBP-4 protease is present in human dominant estrogenic, or healthy
follicles, but not androgen-dominant, or atretic follicles (Chandrasekher et aI., 1995).
However, FSH and estradiol has also been shown to induce IGFBP-4 proteolysis in
human granulosa cell cultures (Iwashita et a1., 1996). Whether estradiol and FSH
directly stimulate the production of a protease by granulosa cells or activate proteolytic
activity through IGF-mediated mechanisms, such as repression ofa proteolytic inhibitor
by IGF-I, remain unknown. However, the addition ofIGF-I, but not FSH, to granulosa
cell cultures stimulated proteolysis of m l-IGFBP-4 (Iwashita et 81. 1998). This suggests
that increased susceptibility ofIGFBP-4 to proteolysis is induced by the binding ofIGFs
to IGFBP-4 (Iwashita et 81., 1998).
The regulation ofIGFBP-4 degradation is also influenced by the IGFBPs in
human follicular fluid. By adding unsaturated IGFBP-I, -2, -3, or more effectively,
IGFBP-4, IGFBP-4 protease activity is significantly reduced, as depicted through
Western immunoblots and scanning densitometry techniques (Cwyfan-Hughes et a1.,
1997). Furthermore, by preincubating IGFBP-3 with an equimolar amount ofIGF-I, the
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inhibition ofIGFBP-4 protease activity can be reversed (Fowlkes et ai., 1995~ Cwyfan-
Hughes et aI., 1997). Therefore, in atretic follicles, where IGF-I concentrations are low
in hwnan follicular fluid, the majority ofIGFBP-3 is unsaturated and can therefore block
the IGFBP-4 protease. thus resulting in IGFBP-4 inhibiting IGF activity. Conversely, in
•
healthy dominant follicles, the increased concentration of IGF would result in most of
IGFBP-3 being saturated with IGF and thus unable to counteract IGFBP-4 protease
activity. The fragmented IGFBP-4, not detectable by Western ligand blotting, has a
decreased affinity for IGF-I and thus can not inhibit IGF activity (Conover et aI., 1993b).
IGF-I becomes more available to the cell receptors which enables the follicle to proceed
into final maturation (Cwyfan-Hughes et aI., 1997). Using murine osteoblasts, Fowlkes
et aJ. (1995) further elucidated that the inhibitory domain in IGFBP-3 may be located in
the non-homologous mid-region of the molecule and/or in the C-tenninal domain
(Fowlkes et aI., 1995). However, in murine osteoblasts, IGFBP-4 can be degraded
without the addition oflGF-1 (Fowlkes et at, 1995).
Durham et al. (I 994b) further demonstrated the effects ofgrowth factors in the
degradation ofIGFBP-4 in normal human osteoblast-like cells. Incubation of 1251_
rhIGFBP-4 with the addition ofIGF-II decreased the amount ofintact IGFBP-4 and
increased the amount of two fragments with molecular weights of 18- and 14-kDa
(Durham et aI., 1994b). IGF-I likewise decreased IGFBP-4levels but was not as
effective as IGF-II (Conover et a1., 1993b~ Durham et al., 1994). Durham et at (1994b)
also demonstrated that in the presence ofIGF-II, TGF~ further increased IGFBP-4
proteolysis. TGFJ3 appears to indirectly enhance IGF-dependent IGFBP-4 proteolysis by
stimulating osteoblast-like cell expression and/or secretion ofa latent IGFBP-4 protease
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(Durham et aI., 1994b). IGF-II may initiate IGFBP-4 protease activity by directly
binding to IGFBP-4 or inactivating an inhibitor to IGFBP-4 proteolysis (Durham et aI.,
19940). Therefore, IGFBP-4 activity in human osteoblast-like cells can be regulated by
IGF-ll and TGF~ (Durham et a1., 1994b), the two growth factors that are abundant in
bone. In contrast, Durham et al. (1994b) found that GH., insulin, or estradiol, did not
alter IGFBP-4 protease activity in human osteoblast-like cells. Likewise, treatment with
EGF also did not alter IGF-dependent IGFBP-4 proteolysis. In rat neuronal cells,
glucocorticoids have also been reported to induce IGFBP-4 protease activity (Cheung et
aI., 1994). Whether these hormones alter ovarian cell IGFBP-4 protease activity remains
to be elucidated.
IGFBP-5 Proteolysis
IGFBP-5 protease activity has been demonstrated in human osteosarcoma cells
(Conover and Kiefer, 1993) and fibroblasts (Camacho-Hubner et aI., 1992), serum of
neonatal fasted pigs (McCusker et aI., 1991b), porcine smooth muscle cells (Cohick et
aI., 1993), bovine (Stanko et aI., 1994), ovine (Besnard et aI., 1996b~ Monget et al.,
1996) and porcine (Besnard et al., 1997) follicular fluid and rat granulosa cells (Fielder et
aI., 1993). Calcium-dependent serine proteases and matrix metalloproteases degrade
IGFBP-5 in bone cells (Gabbitas et aI., 1996). In addition, the proteolytic enzyme to
IGFBP-5 produced by rat gr3.Qulosa cells is cation-dependent (Fielder et aI., 1993).
Evidence using Western immunoblotting techniques, suggests a protease for
IGFBP-5 is apparent in human osteosarcoma cells. During incubation in cell-conditioned
medium, the intact 29-kDa (nonreduced) and 34-kDa (reduced) intact bands for
rhIGFBP-5 are lost and a 16-, 17- and 20-kDa band appears (Conover and Kiefer,
-
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1993b). The addition ofeither IGF-I or -IT increased the intact IGFBP-S, however, the
amount of the fragments were not decreased. Therefore, the addition ofIGF-I or-IT
does not protect IGFBP-S from proteolysis.
In bovine follicular fluid, a 21-kDa fragment, reacting to the IGFBP-5 antiserum
wu detected using Western immunoblotting, along with the intact IGFBP-5 doublet (31-
32-kDa; Stanko et aI., 1994). These two fragments related in size with fragments that
have been identified in serum of neonatal fasted pigs (McCusker et aI., 1991b) as weD as
in media conditioned by pig smooth muscle cells (Cohick et aI., 1993) and human
fibroblasts (Camacho-Hubner et aI., 1992).
Ovine and porcine foDicular fluid likewise contains a protease that degrades
IGFBP-S (Besnard efal., 1996b). During follicular growth IGFBP-5 proteolytic activity
increases slightly and decreases in large atretic follicles (Besnard et aI., 1996b; Besnard
et aI., 1997). The progressive increase in proteolytic activity degrading IGFBP-5 is in
agreement with previous results obtained by Western ligand blotting showing that ovine
and porcine follicular growth is associated with a decrease in IGFBP-S (Besnard et aI.,
1996a; Besnard et a1., 1997). Moreover, degradation ofIGFBP-5 by ovine follicular
fluid was completely inhibited by EDTA and 1, 10 phenanthroline and partially restored
with the addition of calcium chloride and/or zinc chloride (Besnard et aI., 1996b;
Besnard et al., 1997). Thus, based on work by Besnard et aI. (1996; 1997), sheep and
pig follicular fluid contains one or more metalloproteases that degrade IGFBP-2, -3, -4,
and -5.
Various honnones and growth factors may also modulate protease activity for
IGFBP-5. For example, in bone cells, cortisol may enhance IGFBP-5 protease activity
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(Gabbitas et aI., 1996). Likewise, in rat granulosa cells, FSH (Fielder et aI., 1993; Liu et
al., 1993) induces production of an IGFBP-5 protease. However. IGF-I or -IT (Fielder
et aI., 1993) blocks this proteolytic activity, as also demonstrated in fibroblast-
conditioned medium (Camacho-Hubner et aI., 1993). Therefore, FSH may induce an
IGFBP-5 protease, or alternatively, FSH may decrease an IGFBP-5 protease inhibitor.
leading to the activation of the IGFBP-5 protease.
IGFBP-6 Proteolysis
Unlike the other binding proteins, fewer investigations ofprotease8 for the more
recently identified IGFBP-6 have been reported. However, like the aforementioned
binding proteins, IGFBP-6 is also affected by proteolytic activity. Neumann et aI.
(1998), who demonstrated O-g1ycosylation ofIGFBP-6, also investigated degradation of
nonglycosylated and glycosylated IGFBP-6. When chymotrypsin was incubated with
IGFBP-6, 1 ng and lOng chymotrypsin cleaved intact nonglycosylated and glycosylated
IGFBP-6, respectively (Neumann et al., 1998). Clearly, additional research is needed to
determine if IGFBP-6 proteolytic enzymes exist within the ovarian follicle.
Table 1
Binding affinities of the various IGFBPs for IGF-I and IGF-II
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MW Relative Affinity Affinity Constants Affinity Constants
(kDa) for IGF-I· for IGF-II·
IGFBP-l 25-34 IGF-II> IGF-I 6 x 109 1.2 x 1010 ':)~ ..
IGFBP-2 29-40 IGF-II> IGF-I 1.3 x 109 2.3 X 109
~;-
~~
150b 1 X 1010 1.2 X 1010
~l
IGFBP-3 IGF-I= IGF-II :!
2 x 1010 1.9 X 1010
~)
IGFBP-4 24-30 IGF-I = IGF-II I)
2.6 x 1010 2.3 X 1010
'to
IGFBP-5 29-31 IGF-I = IGF-II l)
·to
8 X lOB 1.7 X 1010
t)
IGFBP-6 21-32 IGF-II» IGF-I ....
....
IGF type I 95-135 IGF-I» IGF-II 1 x 109 1 X 108
:,
::.
receptor ci
IGF type II 230-270 IGF-II » IGF-I 0.5 x 107 1 X 109
.,
')
receptor :;:
'.
·From Conover, 1996 "...
:r~ of intact circulating form; on ligand blots, IGFBP-3 appears as a doublet at 40-43 "\~)
kDa. ;3,
Table 2
Percent amino acid homology of the IGFBPs across species·
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Bovine Amino Porcine Ovine Human Mouse Rat
Acidsd
:>IGFBP-l (263) 234 NAc NA 68 (259) 71 (272) 72 (272) ~ ..
~I~
IGFBP-2 (53) 289 70 (23) 92 (317) 72 (328) 64 (305) 64 (305) Jj-
~t
IGFBP-3 (291) 264 89 (266) NA 82 (291) 78 (291) 80 (292) :1
~I
IGFBP-4 (258) 237 88 (16) 98 (237) 97 (258) 89 (254) 89 (254) I)
' ..
IGFBP-5 (111) 252 99 (271) NA 99 (272) 97 (254) 97 (254) II...
t)
IGFBP-6 (122) 216 NA NA 83 (240) 71 (238) 67 (226) '-
'-~umbers in parenthesis indicate the amino acid length by which homology
:,
::.
--comparisons were made. t).,
~uropean Bioinfonnatics Institute r):F
cSwiss-Prot database '.
dCoverley and Baxter, 1997 -.:r~A= not available
-..
l)
;3
.
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CHAPTER III
Production of the Insulin-like Growth Factor Binding
Proteins by Bovine Granulosa and Thecal Cells:
Regulation by Metabolic Hormones
Abstract
To detennine the honnonal effects on IGFBP production, granulosa and thecal
cells from small (1 to 5 mm) and large (~ 8 mm) bovine follicles, respectively, were
collected, cultured for 2 days an 100.10 fetal calf serum, washed and cultured in serum-free
medium for an additional 24 h with various hormone treatments, arranged in three
experiments. Following treatment, cells were enumerated and medium was collected,
concentrated 10-fold and subjected to ligand blotting. Experiment I revealed that ~ 1. 5 x
lOS viable cells at plating were needed for maximal IGFBP production by granulosa and
thecal cells. The major forms ofIGFBPs produced were a 27-34-kDa IGFBP (IGFBP-2
and -5), and a 20- and IS-kDa IGFBP (lGFBP-4) by the granulosa cells and a 40-44-kDa
IGFBP (lGFBP-3), 34-kDa IGFBP (IGFBP-2), 27-29-kDa IGFBP (IGFBP-5) and a 24-
and 22-kDa IGFBP (IGFBP-4) by the thecal cells. In Experiment 2A, insulin stimulated
production of the 27-29-kDa IGFBP (IGFBP-5) by thecal cells, and basic fibroblast
growth factor (bFGF) inhibited the insulin-induced increase whereas only the
combination of insulin and LH stimulated production of the 22-1cDa IGFBP (IGFBP-4).
Production of the 27-34-kDa IGFBP (IGFBP-2/5) by granulosa cells in Experiment 2B
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was inhibited by insulin, with EGF and bFGF further enhancing insulin's inhibitory
effect. In Experiment 3A, insulin enhanced production of the 27-29-kDa IGFBP
(IGFBP-5) by thecal cells whereas glucagon blocked insulin's stimulatory effect. In
contrast, insulin and glucagon synergistically diminished production of the 24-kDa
IGFBP (IGFBP-4) whereas insulin with either glucagon or cortisol decreased
production of the 22-kDa IGFBP (IGFBP-4) by the thecal cells. In Experiment 3B,
production of the 27-34-kDa IGFBP (lGFBP-2/5) by granulosa cells was attenuated in
the presence ofcortisol with or without insulin and insulin with glucagon. Treatment
with glucagon and cortisol decreased whereas insulin increased production of the 20-
and 18-kDa IGFBPs (IGFBP-4), respectively, by granulosa cells. These results suggest
that production of IGFBP-5 and -4 by thecal cells and IGFBP-2, -5, and -4 by granulosa
cells are differentiany affected by hormonal treatments.
Introduction
Folliculogenesis, or ovarian follicular growth, is an essential function of the
reproductive system. During a normal estrous cycle, a network of hormonal events,
which consist of peptide and steroid hormones, as well as growth factors, interact.
Insulin-like growth factors-I and -II (lGF-I and -II) are two such examples ofgrowth
factors that playa role in modulating ovarian folliculogenesis. Folliculogenesis is an
important factor that maintains overall production efficiency, it is crucial that the
ovarian processes that controls follicular growth be understood in an effort to assess the
reproductive system. Through an autocrine, paracrine, and endocrine fashion, the IGF's
stimulate the growth and differentiation ofgranulosa and thecal cells as well as enhance
---
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steroidogenesis (for review see Spicer and Echternkamp, 1995). Concentrations ofIGF-
I remain constant during the final stages of follicular growth (Stewart et ai., 1996~ de la
Sota et ai., 1996; Funston et aI., 1996), indicating that the amount ofIGF binding to its
receptor and ultimately follicular growth, may be dictated by the insulin-like growth
factor binding proteins (IGFBPs). Levels ofIGFBPs in follicular fluid change
dramatically during folliculogenesis. Specifically, IGFBP-2, a 22-kDa IGFBP
(presumably IGFBP-4) and a 27-29-kDa IGFBP (presumably IGFBP-5) is
predominately localized in large subordinate and small bovine follicles, with little to no
activity ofthese three IGFBPs detected in the dominant follicles (de la Sota et aI., 1996;
Funston et aI., 1996; Stewart et aI., 1996). Later during the cycle (approximately day
10) when the follicle is undergoing atresia, levels ofIGFBP-2, -4, and -5 levels increase
in the dominant follicle (Stewart et aI., 1996). The varying pattern of these IGFBPs
through the estrous cycle suggests that the low molecular weight IGFBP are hormonally
regulated. In contrast, levels ofIGFBP-3 remain constant during folliculogenesis (de la
Sotael aI., 1996; Funston et aI., 1996; Stewart et aI., 1996).
The hormones and growth factors that regulate follicular IGFBP production in
cattle have not been determined. In cultured porcine granulosa cells, FSH inhibits,
insulin stimulates, and EGF has no effect on IGFBP-2 production (Mondschein et al.,
1990; Grimes and Hammond, 1992; Grimes et aI., 1992). Both IGFBP-3 and -2 inhibit
IGF-I induced steroidogenesis in bovine granulosa and thecal cells (Spicer et aI., 1997;
Spicer and Chamberlain, 1999). Thus, hormonal changes can alter the action ofIGFs
via changes in IGFBP. The scope of this study was to determine the hormonal
regulation ofIGFBP production by bovine granulosa and thecal cells, with specific
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focus on the effects of insulin, luteinizing hormone (UI), follicle stimulating hormone
(FSH), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), cortisol,
and glucagon on IGFBP production.
Materials and Methods
Reageuu aDd Hormones
The reagents used in this study include: Dulbecco's Modified Eagle's Medium
(DMEM), Ham's F-12, insulin (bovine; 25.7 U/mg), fetal calf serum (FCS), cortisol,
protease, collagenase, hyaluronidase, DNase, and acrylamide, all obtained from Sigma
Chemical Company (St. Louis, MO); recombinant human basic fibroblast growth factor
(bFGF) with carrier obtained from R&D Systems (Minneapolis, MN)~ recombinant
human glucagon and recombinant human EGF obtained from Bachem California
(Torrence, CA); bovine LH (USDA-bLH-B5: LH activity 2.1 x LH-SI U/mg~ FSH
activity < 1.0 % by weight) and ovine FSH (USDA-oFSH-19-SIAFP-I-2, FSH activity
94 x NllI-FSH-SI D/mg; LH activity .025 x NllI-LH-SI D/mg) obtained from the
USDA, Animal Hormone Program (Beltsville, MD); bovine serum albumin (protease
free) obtained from lntergen Co. (Purchase, NY); recombinant bovine IGF-II obtained
from Monsanto (St. Louis, MO); 200,/0 (w/v) sodium dodecyl sulfate solution (SDS)
from Amresco (Solon, OH)~ and nitrocellulose transfer membrane (.45 J..Lm pore size)
from Midwest Scientific (St. Louis, MO).
Cell Culture
---
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Ovaries from slaughtered pregnant and nonpregnant beef and dairy cattle were
collected at a local commercial abattoir. The ovaries were placed in saline (.15 M NaCI)
and transported to the laboratory «120 min) where small follicles (1 to 5 mm) were
aspirated using a 20 gauge needle (38.1 mm) and 3 mL syringe to collect granulosa cells
as previously described (Langhout et aI., 1991). The granulosa cells were wuhed 3
times in serum-free medium by centrifugation at 200 X g (for 5 to 7 min). The cells
were then resuspended in medium containing 1 mglmL collagenase and 0.01 mg/mL
DNase to prevent clumping of the cells.
Thecal cells were collected from large follicles (~ 8 mm) by dissection as
previously described (Stewart et aI., 1995). Briefly, after isolation, the theca intema was
tom into small pieces and enzymatically digested for 1 hat 37° C on a rocking platform.
Any tissue not digested after the incubation period was removed via filtration through a
syringe filter holder with a metal screen (149 llm mesh; Gelman Sciences, Ann Arbor,
Ml). The thecal cells were then washed in serum-free medium by centrifugation (at 50
X g for 4 min) and resuspended in medium containing 1 mg/mL collagenase and 0.01
mglmL DNase. The number of viable granulosa and thecal cells was determined by the
trypan blue exclusion method and averaged 63.00,/0 and 94.8%, respectively.
Medium consisted of a 1: 1 mixture ofDulbecco's Modified Eagle's Medium
(D"MEM) and Ham's F-12 containing 0.12 roM gentamicin, 20 mM glutamine, and 38.5
mM sodium bicarbonate. Approximately 3 x 1005 viable cells (in 30-80 J..I.I) were placed
into each well ofFalcon multiwell plates (No. 3047~ Becton Dickinson, Lincoln Park,
NJ) containing 1 mL medium with 10% FCS, unless stated otherwise. Cells were
cultured at 38.5° C with 95% air-5% CO2 atmosphere, and the medium was changed
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approximately every 24 h. Cell proliferation was monitored daily using phase contrast
microscopy (Fig. 1A and 2A). During the first 2 days of incubation, cells were cultured
in I ()O!cl FCS-containing medium, after which, the cells were washed twice with serum-
free medium (0.5 roL), followed by 24 h hormonal treatments in 0,5 mL of serum-free
medium containing 0,25 mg/mL ofBSA (to minimize loss of the IGFBPs).
Experiment I was designed to determine whether cell density had any affect on
IGFBP production by thecal (Experiment lA) and granulosa cells (Experiment lB),
Thecal cells (Experiment IA) from large follicles were plated at densities of .25, .5, 1.0,
1.5,3.0, or 6.0 (x lOs) cells/well in medium containing 10% FCS for 48 h, After 48 h,
the media was replaced with serum-free medium containing insulin (l00 ng/mL) and
LH (100 ng/roL) and incubated for an additional 24 h. In Experiment lB, granulosa
cells from small follicles were plated at densities of .25, .5, 1.0, 1.5, and 3,0 (x lOS)
cells! well in medium containing 10% FCS. After 48 h, the media was replaced with
serum-free medium containing insulin (l00 ng/mL) and FSH (50 ng/mL) and incubated
for an additional 24 h.
Experiment 2A was designed to determine whether insulin, LH, EGF and/or
bFGF affected IGFBP production by thecal cells. Thecal cells from large follicles (~ 8
mm) were cultured for 48 h as described above, For the next 24 h the cells were
cultured in serum-free medium containing no additions (control), insulin (100 ng/mL),
LH (100 ng/mL), LH (100 ng/mL) plus insulin (100 ng/mL), EGF (10 ng/mL) plus
insulin (100 ng/mL) or bFGF (10 ng/mL) plus insulin (100 ng/mL).
Experiment 2B was designed to determine whether insulin, FSH, EGF, and/or
bFGF affected IGFBP production by granulosa cells. After the 48 h incubation period
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in medium containing 100,10 FCS, granulosa cells from small (1 to 5 rom) follicles were
incubated for another 24 h in serum-free medium containing no additions (control),
insulin (100 nglmL), FSH (50 nglmL), FSH (50 nglmL) plus insulin (100 nglmL), EGF
(10 nglmL) plus insulin (100 nglmL), or bFGF (10 nglmL) plus insulin (100 nglmL).
Experiment 3 was designed to determine whether insulin, cortisol and/or
glucagon influenced IGFBP production by thecal (Experiment 3A) or granulosa
(Experiment 3B) cells. After the 48 h incubation period in medium containing 100,10
FCS, thecal cells from large (~8 mm) follicles and granulosa cells from small (1 to 5
mm) follicles were incubated for another 24 h containing no additions (control), insulin
(100 nglmL), cortisol (30 ng/mL), insulin (100 ng/mL) plus cortisol (30 ng/mL),
glucagon (300 pg/mL), or insulin (100 ng/mL) plus glucagon (300 pg/mL).
Determination of numbers of granulosa and thecal cells
After the treatment period had elapsed, medium from each well was collected
individually and frozen at (-20°C) for later use. The number ofgranulosa and thecal
cells were then determined using a Coulter counter (Model Zm; Coulter, Haileah, FL)
as previously described (Langhout et aI. 1991; Stewart et aI., 1995). Briefly, the cells
were washed twice with.5 mL of .15 M NaCl followed by the addition of.5 mL of
trypsin (.25% wtJvol~ for 20 min at 25°C). Following trypsin exposure, the cells were
scraped from each well, diluted in .15 M NaCI, and enumerated.
Concentration of spent medium
To concentrate the IGFBPs, the media samples collected after cells were
exposed to treatment for 24 h were ultrafiltrated using Centricon concentrators with a
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molecular weight (MW) limit of3,000 (Arnicon, Inc., Beverly, MA). The spent
medium was concentrated approximately 10-fold. Briefly, 400 J,.LL of the spent media
was placed inside the sample reservoir of the concentrator and centrifuged at 5322 X g
for approximately 80 min. After centrifugation, the filtrate vial was discarded, the
sample reservoir was inverted and re-centrifuged for 5 min at 591 X g to transfer the
retentate into the retentate vial. Final volumes, ranging from 29 to 70 J,1L were
measured to record the concentration factor of the sample; this value was used to correct
data.
Gel electrophoresis of tbe IGFBPs
The concentrated media samples were assessed for IGFBP activity based on
molecular weight using one-dimensional, reducing, sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (Laemmli,
1970; Stewart et al., 1996). Briefly, 12.5 J,.LL of the concentrated sample was mixed with
12.5 ~ ofLaemmli sample buffer (BIORAD, Hercules, CA). After heat treatment (3
min at 100 °C) to denature the proteins, samples were centrifuged at 4657 X g for 3 min
and individually added to the 12-lane SDS-PAGE. Twenty-five J,.LL ofa wide range
color marker (MW 6,500 to 205,000, Sigma, St. Louis, MO) and a mixture of4 uL
bovine follicular fluid with 21 ~ ofthe sample buffer were included to serve as
controls. The samples were electrophoresed overnight (approximately 18 to 20 h) at
constant current (25 to 35 amps) and varying voltage. Following electrophoresis, the
gels were electrophoretically transferred to nitrocellulose paper (Midwest Scientific, St.
Louis, MO) for 2.5 to 3.0 h. Each nitrocellulose paper was then labeled with 125I_IGF_II
(approximately 15,000 cpmlO.1 mL; total volume=12 mL) and placed on a rocking
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platfonn at 40 C overnight. The next day, the blots were washed in a Tris-buffered
saline (TBS) with 0.1% Tween followed with additional washings with only the TBS.
The nitrocellulose blots were then dried and placed on X-ray film for approximately 14
d at _800 C. At the end ofthe 14-d period, X-ray films were developed and individual
bands were densitometrica1ly analyzed using Molecular Analyist (BID-RAn, Hercules,
CA).
Statistical Aoalysis
Data are presented as the least squares means ± SE. Each experiment was
replicated 2 to 3 times with different pools ofgranulosa cells, each collected from 20 to
60 ovaries, whereas each pool of thecal cells was obtained from 6 to 8 follicles from 4
to 10 cows. For each experiment, treatments were applied in triplicate culture wells.
Using the general linear model procedures of SAS, treatment effects and interactions
were determined. Specifically, main effects (treatments and replicates) and interactions
on dependent variables (i.e., IGFBP production) were analyzed. IGFBP production,
which was corrected for final cell numbers and the concentration factor, was expressed
as arbitrary densitometric units per 10.5 cells per 24 h. Specific differences in IGFBP
production between treatments were determined using PDIFF (SAS, 1988) if significant
main effects were observed.
Results
Experiment lA: Effect of thecal cell plating density on IGFBP production
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Thecal cells produced at least five forms ofIGFBP: a 42-44-kDa (lGFBP-3), a
34-kDa (IGFBP-2), a 27-29-kDa IGFBP (IGFBP-5), a 24-kDa IGFBP (IGFBP-4) and a
22-kDa IGFBP (IGFBP-4). IGFBP-4 (24-kDa) and IGFBP-5 were the major IGFBPs
produced (Fig. IB). Plating density significantly (p < .05) affected production of all
IGFBPs (Fig. 3). Increasing thecal cell plating density from 1 to 3 X 10' cells/well
increased (p < .OS) production of all the IGFBPs on a per cell basis. A plating density of
6.0 x 10' cells/well had no further influence on production ofIGFBP-3, -2, -5, and -4
(22-kDa) from that observed with 3.0 x 10' cells/well. A similar plateau effect was
demonstrated with the 24-kDa IGFBP (IGFBP-4) subsequent to a plating density of 1.5
x 10' cells/well (Fig. 3D).
After 3 d in culture, thecal cell numbers averaged .48, .90, 1.64,2.15,3.57, 5.37,
± .05 x 10' cells/well for .25, .5, 1.0, 1.5,3.0, and 6.0 x lOs cells plated per well.
Increasing plating density from 0.25 x 10' to 6.0 X 10' cells/well resulted in proportional
increases (p < .05) in thecal cell numbers after 3 d in culture.
Experiment IB: Effect of granulosa cell density on IGFBP production
Granulosa cells produced at least three forms ofIGFBPs; a 27-34-kDa IGFBP
(IGFBP-2 and -5), an 18-and 20-kDa IGFBP (IGFBP-4); IGFBP-2/5 was clearly the
predominant IGFBP produced (Fig. 2B). Plating density affected granulosa cell
production ofIGFBP-2/5 (p < .05) and IGFBP-4 (20-kDa and 18-kDa, p < .05).
Increasing granulosa cell plating density from .25 x 10' to 1.5 x 10' cells/well increased
production (on a per cell basis) ofIGFBP-2/5 and IGFBP-4 (20-kDa and 18-kDa, Fig.
4). However, increasing plating densities from 1.5 to 3.0 x lOS cells/well did not (p >
r
us
.05) further enhance production ofIGFBP-2/5 and the 18-kDa IGFBP (IGFBP-4, Fig.
4).
After 3 d in culture, granulosa cell numbers averaged 0.45, 1.13,2.04,2.49, and
3.35 ± 0.10 cells/well for 0.25,0.50, 1.0, 1.5, and 3.0 x lOs cells plated per well,
respectively. Increasing plating density from .25 x lOs to 3.0 x lOS cells/well, resulted in
proportional increases (p < .05) in granulosa cell numbers after 3 d in culture.
Experiment 2A: EfTect ofiDsulin, LB, EGF, and bFGF on thecal eell IGFBP
produetion
As in Experiment IA, the two major IGFBPs produced by thecal cells was the
27-29-kDa (IGFBP-5) and 24-kDa (IGFBP-4) IGFBP. Treatment had no effect (p>
.10) on IGFBP-2 production, but tended (p < .10) to affect production ofIGFBP-3 and
the 24-kDa IGFBP (IGFBP-4, Table 3). Insulin and insulin plus LH tended (p < .10) to
increase production of the 24-kDa IGFBP (IGFBP-4) whereas the combined treatments
of insulin with either LH, EGF or bFGF tended (p < .10) to increase production of
IGFBP-3. In contrast, significant treatment effects on IGFBP-5 and the 22-kDa IGFBP
(IGFBP-4) were observed (Fig. 3). Insulin increased (p < .05) production ofIGFBP-5,
the predominant IGFBP in this experiment, whereas LH had no affect (p > .10) on basal
or insulin-stimulated IGFBP-5 production. EGF had no effect whereas bFGF blocked
the insulin-induced increase in the production of the IGFBP-5 (Fig. SA). Insulin plus
LH increased production of the 22-kDa IGFBP (IGFBP-4) when compared to the
control (p < .05, Fig. 58). Neither LH or insulin alone significantly affected production
of the 22-kDa IGFBP (IGFBP-4).
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The influence of the treatments on thecal cell numbers is depicted in Table 3.
Insulin (p < .05) increased the number of thecal cells, but LH had no affect on basal or
insulin-induced thecal cell numbers. In contrast, both EGF and bFGF further increased
(p < .05) the insulin-stimulated cell numbers.
ExperimeDt 2B: Effect of FSH, insulin, EGF, and bFGF by graDulo•• cell IGFBP
prodUctiOD
As in Experiment IB, the major IGFBP produced by the granulosa cells was the
27-34-kDa IGFBP (lGFBP-2/5). Treatments had no effect (p > .10) on the 18-kDa
(IGFBP-4) and 20-kDa IGFBP (lGFBP-4, Table 4). In contrast, treatment effects were
observed on IGFBP-2/5 (p < .05). Treatment with insulin alone and FSH plus insulin
decreased production ofIGFBP-2/5. However, the addition ofFSH alone had no effect
(Fig.6A). Both EGF and bFGF further augmented the inhibitory effect of insulin on
production ofIGFBP-2/5 (Fig. 6B).
Table 4 shows the effects of the treatments on granulosa cell numbers. Insulin
and insulin plus FSH increased (p < .05) granulosa cell numbers similarly. EGF and
bFGF further increased (p < .05) insulin-induced granulosa cell numbers. However,
FSH had no effect (p> .10) on basal or insulin-induced cell numbers (Table 4).
Experiment 3A: Effect of insulin, glucagon and cortisol on thecal cell IGFBP
production
The predominant IGFBP produced by thecal cells of these experiments was the
24-kDa IGFBP (IGFBP-4). Treatments had no effect (p > .10) on IGFBP-3 production
by the thecal cells whereas a trend (p < .10) for a treatment effect was observed with
IGFBP-2 (Table 5). Production ofIGFBP-2 was greater (p < .J 0) in cells treated with
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insulin than those treated with either glucagon or cortisol (Table 5). Insulin tended (p<
.10) to increase IGFBP-2 production in the presence ofglucagon. In contrast, treatment
effects were observed on IGFBP-5 (p < .05), the 24-kDa (IGFBP-4, p < .05), and 22-
leDa (IGFBP-4, p < .05) IGFBP (Fig. 7). Production ofIGFBP-5 (Fig. 7A) was
stimulated (p < .05) by insulin alone whereas other singular treatments (i.e., glucagon
and cortisol) were without effect (p> .05). Glucagon inhibited insulin-stimulated
production ofIGFBP-5 whereas cortisol had no effect (Fig. 7). Production of the 24-
leDa IGFBP (IGFBP-4) was inhibited by the combination of insulin and glucagon,
whereas other treatments were without effect (Fig. 7B). Likewise, production ofthe 22-
leDa IGFBP (IGFBP-4, Fig. 7C) was inhibited by insulin plus glucagon, cortisol alone,
and cortisol plus insulin.
Table 5 shows the effects of the treatments on cell numbers. Insulin increased
(p < .05) the number of thecal cells, whereas glucagon and cortisol had no effect (p >
.10) on basal or insulin-induced cell numbers (Table 5).
Experiment 3D: Effect of insulin, glucagon, and cortisol on granulo.a cell IGFBP
production
The major IGFBP produced by granulosa cells in this experiment was the 27-34-
kDa IGFBP (IGFBP-2/5). Treatment effects were observed on IGFBP-2/5, the 20-kDa
(IGFBP-4), and 18-leDa (IGFBP-4) IGFBPs (p < .05, Fig. 8). Cortisol, insu·lin plus
glucagon, and insulin plus cortisol inhibited (p < .05) production ofIGFBP-2/5; singular
treatment of insulin or glucagon had no effect (Fig. 8A). In contrast, production of the
20-kDa (IGFBP-4) was inhibited (p < .05) by singular treatment of cortisol or glucagon
and by the combination of insulin and glucagon; insulin with or without cortisol had no
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effect (p> .10, Fig. 8B). The 18-kDa IGFBP (IGFBP-4) was stimulated (p < .OS) by
insulin treatments alone, while all other treatments were without effect (p > .10, Fig.
8e).
Granulosa cell numbers averaged 1.63, 1.61, 1.19, 1.04,0.94, and 0.84 ± .16 x
10" cells/well for control, insulin, glucagon, cortisol, insulin plus glucagon and insulin
plus cortisol treatment groups, respectively. Insulin increased (P < .OS) granulosa cell
numbers whereas glucagon or cortisol had no effect (P > .10) on basal or insulin-
induced cell numbers.
Discussion
Results of the present study revealed that 1) a 42-44-kDa (IGFBP-3), 34-kDa
(IGFBP-2), 27-29-kDa, 24-kDa and 22-kDa IGFBP was produced by thecal cell
cultures (Fig. IB) while a 27-34-kDa, 20-kDa and 18-kDa IGFBP was produced by
granulosa cell cultures (Fig. 2B), 2) insulin enhanced production of the 27-29-kDa and
18-kDa IGFBP by thecal (Table 6) and granulosa cells (Table 7), respectively, 3) alone
LH or FSH had no affect on thecal (Table 6) or granulosa (Table 7) cell IGFBP
production, 4) EGF and bFGF decreased production of the 27-34-kDa IGFBP by
granulosa cells (Table 7), 5) alone glucagon had no effect on thecal or granulosa cell
IGFBP production, but decreased IGFBP production in the presence of insulin (Table 6
and 7) and, 6) alone cortisol decreased production of the 22-kDa IGFBP by thecal cells
and the 27-34-kDa and 20-kDa IGFBP by granulosa cells (Table 6 and 7).
Based on immunoblotting techniques from other laboratories, the 42-44-kDa is
likely IGFBP-3, the 34-kDa is likely IGFBP-2, the 27-29-kDa is likely IGFBP-5 and the
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24-kDa is likely IGFBP-4 (Stanko et aI., 1994~ de la Sota et aI., 1996; Funston et aI.,
1996). While the identity of the 22-, -20, and I8-leDa bands remains undetermined,
results from human follicular fluid (Cataldo and Giudice, 1992a,b) and rat granulosa
cell conditioned medium (Liu et aI., 1993) suggest that these IGFBPs may represent
different glycosylated forms ofIGFBP-4. In addition., 27-34-kDa by the granulosa cells
is likely to be a composite of two IGFBPs, IGFBP-2 and -5. Because the bands
identifying the two different IGFBPs were indistinguishable on the ligand blots, the
IGFBPs were scanned and analyzed as one.
The IGFBPs most influenced by hormone treatments were IGFBP-5 and the 24-
leDa (IGFBP-4) IGFBPs by the thecal cells and IGFBP-5 and -2 by the granulosa cells,
the major IGFBP produced by each cell type (Table 6 and 7). In contrast, IGFBP-3 and
IGFBP-2, minor IGFBPs produced by the thecal cells, were not influenced by any
hormone regime. The lack of response oflGFBP-2 as well as IGFBP-3 to hormone
treatments in cultured thecal cells in the current study may stem from the low
expression of these mRNA in the thecal cells. In support of this suggestion, in situ
hybridization experiments in sheep follicles indicated that the IGFBP-2 mRNA is
primarily expressed in granulosa cells whereas, IGFBP-4 and -5 mRNA are expressed
in thecal cells in healthy ovine follicles (Besnard et al., 1996) and that IGFBP-3 mRNA
is low or undetectable in ovine (Perks and Wathes, 1996) and bovine (Kirby et aI.,
1996; Yuan et aI., 1998) follicles and ovaries. However, both IGFBP-2 and -5 are
secreted by cultured ovine granulosa cells (Armstrong et aI., 1996; Monget et aI., 1998).
In the rat, thecal, but not granulosa cells contain IGFBP-2 mRNA whereas the converse
is true for the mouse (Ricciarelli et aI., 1991; Erickson et aI., 1995; Adashi et aI., 1997).
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In both the rat and mouse, IGFBP-4 mRNA is found in mainly granulosa cells with
some expression in thecal cells (Nakatani et aI., 1991; Erickson et aI., 1992a; Adashi et
at, 1997), whereas IGFBP-5 mRNA is found in granulosa but not thecal cells (Erickson
et aI., 1992b; Adashi et aI., 1997). Thus, species differences may exist in terms of
which cell type produce a particular IGFBP. Similar to previous results in rats, bovine
thecal cells, but not granulosa cells produced IGFBP-3 in the present study (Liu et aI.,
1993; Nakatani et aI., 1991; Ricciarelli et aI., 1991; 1992). Although IGFBP-3 is the
primary IGFBP found in bovine follicular fluid (Stewart et aI., 1996; Funston et aI.,
1996; Echternkamp et aI., 1994), the levels ofIGFBP-3 in follicular fluid reflect those
found in the systemic circulation ofcattle (Stewart et aI., 1996), suggesting that the
majority ofIGFBP-3 found in follicular fluid may be transuded from blood. Lack of
hormone responsiveness ofIGFBP-3 production by thecal cells as well as low amounts
produced, support this conclusion.
Similar to previous research, EGF stimulated mitogenic activity of insulin in
cultured granulosa (Savion et aI., 1981; May et a1., 1988) and thecal cells (May et aI.,
1992; Vernon and Spicer, 1994; Spicer and Stewart, 1996) in the present study. EGF
inhibits steroidogenesis ofboth cell types (Langhout et aI., 1991; Spicer and Stewart,
1996). EGF plus insulin inhibited production of the IGFBP-2/5 by the granulosa cells,
but had no effect on thecal cell IGFBP production. Similar to our finding with thecal
cells, EGF, or its homologue, TGFa., had no effect on IGFBP-2 and -3 production by
cultured porcine granulosa cells (Mondschein et al., 1990), IGFBP-4 and -5 mRNA
levels in whole ovarian homogenates of rats (Chamoun et aI., 1999), IGFBP-2
production by cultured human intestinal epithelial cells (Oguchi et aI., 1993) and
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vascular smooth muscle cells (Boumer et aI., 1992; Cohick and Clemmons, 1993), and
IGFBP-3 production by cultured human intestinal (Oguchi et aI., 1993) or retinal
pigment-epithelial cells (Feldman and Randolph, 1994). However, EGF increased
IGFBP-3 production by cultured rat astroblasts (Loret et aI., 1991) and decreased
IGFBP-3 production in human cervical epithelial cells (Andreatta-Van Leyen et aI,
1994) and keratinocytes (Wraight and Werther, 1995), as well as mouse embryo
fibroblasts (Villaudy et aI., 1991). The lack of consistency resulting from EGF
treatment also applies to IGFBP-4. Our observation that IGFBP-4 production by thecal
or granulosa cells was not affected by EGF treatment agrees with data from cultured
human fibroblasts (Conover et aJ., 1993b), but disagrees with data from cultured human
intestinal epithelial cells (Oguchi et aI., 1993). Consistent with our findings in
granulosa cells, EGF decreased IGFBP-5 gene expression by rabbit proximal tubular
cells (Yap et aI., 1997). Collectively, these results suggest that the regulation ofIGFBP
production by EGF treatment differs with cell type. The physiologic consequences of
the inhibitory effect ofEGF on ovarian IGFBP synthesis could allow for more available
IGF during early follicle growth.
Like EGF, bFGF stimulated proliferation of thecal and granulosa cells in the
present and previous studies (Gospodarowicz and Bialecki, 1978; 1979; Gospodarowicz
et aI., 1985; Wandji et a1., 1992; Vernon and Spicer, 1994; Spicer and Stewart, 1996);
bFGF also inhibits steroidogenesis of both cell types (Vernon and Spicer, 1994; Spicer
and Stewart, 1996). In the present study, bFGF decreased production ofIGFBP-2/S by
the granulosa cells and IGFBP-5 and the 22-kDa IGFBP (IGFBP-4) by the thecal cells.
Previous research i.ndicates that the influence ofbFGF, like EGF, is dependent on the
--
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particular IGFBP evaluated and cell type used. For example, IGFBP-2 production was
not influenced by bFGF treatment in cultured vascular smooth muscle cells (Boumer et
aI., 1992; Cohick and Clemmons, 1993; Cohick et aI., 1995) but was increased in
human cultured neuroblastoma cells (Babajko et aI., 1997). However, treatment of
bFGF to fetal rat osteoblasts (Canalis et aI., 1993; Ganalis and Gabbiw. 1995) and rat
whole ovarian homogenates (Chamoun et aI., 1999), decreased IGFBP-5 protein as well
as its mRNA which agrees with the current research. Also in agreement with the
present study, bFGF had no effect ofIGFBP-4 and -5 mRNA levels in rat whole ovarian
homogenates (Chamoun et al., 1999) and rat granulosa cells (Choe et aI., 1997). In
comparison, IGFBP-3 production by thecal cells was not effected by bFGF in our
current work. Studies using mouse fibroblasts (Blat et al., 1989), chick embryo
fibroblasts (Blat et a1., 1989), human keratinocytes (Wraight and Werther. 1995), and
rat astroblasts (Loret et aI., 1991) found a decrease in IGFBP-3 levels with bFGF
treatments. Similar to what was suggested for EGF, bFGF may enhance follicular
growth by increasing bioavailable IGF-I via decreased IGFBP production.
Similar to previous studies using porcine (Mondschein et aI., 1990; Grimes et
aI., 1992), rat (Liu et aI., 1993; Fielder et al., 1993; Choi et aI., 1996), and polycystic
human (San Roman and Magoffin, 1992) granulosa cells, FSH decreased production of
IGFBP-2/5 by bovine granulosa cells when co-incubated with insulin. In contrast, FSH
treatment was ineffective at modulating IGFBP-2 production by cultured human
(Cataldo et al., 1993) and ovine (Armstrong et a1.,1996) granulosa cells. Echternkamp et
al. (1994) likewise indicated that administration of exogenous FSH to cyclic cows had
no effect on the low molecular IGFBPs (i.e., IGFBP-2, -4, and -5) in large (~ 8 mm)
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estrogen-inactive foHicles, but decreased their amounts in large estrogen-active
follicles. Erickson et aI. (1994) and Piferrer et aI. (1997) showed that low doses ofFSH
(s 3 nglmL) increased IGFBP-4 production whereas high doses (~ 10 nglmL) inhibited
IGFBP-4 levels by cultured rat granulosa cells. Similar biphasic effect ofFSH was
observed on IGFBP-5 production by cultured rat granulosa cells (Adashi et aI., 199Oa;
1991; Fielder et al., 1993). The negative effect of the high doses ofFSH was due to
FSH stimulating proteolysis ofIGFBP-4 and -5 (Liu et at, 1993; Fielder et aI., 1993;
Piferrer et aI., 1997) as well as decreasing IGFBP-4 mRNA levels (Erickson et aI.,
1994; Choi et al., 1996). Thus, the inconsistent effects ofFSH among studies may be
due to the variable concentration ofFSH used among experiments, the physiological
status of the follicle, and/or species differences. If indeed low doses ofFSH stimulate,
and high doses decrease production of the IGFBP-2, -4, and/or -5, then this would
suggest that IGFBP-2, -4, and -S may be developmentally regulated during the estrous
cycle.
In contrast to FSH, LH did not significantly affect production ofany of the
IGFBPs by bovine thecal cells of the present study. Voutilainen et al. (1996) reported
that LH treatment increased IGFBP-5 mRNA levels in cultured thecal cells. Giudice et
at (1991) showed that the addition ofhCG to cultured human luteinized granulosa cells
increased IGFBP-4 production 6- to 8-fold above the controls. Moreover, LH treatment
caused a dose- and time-dependent increase ofIGFBP-4 production in cultured ovine
thecal cells (Armstrong et aI., 1996) and IGFBP-4 rnRNA in cultured bovine thecal
cells (Armstrong et aI., 1996). Previously, LH had no effect on IGFBP-2 production in
human granulosa cells (Giudice et aI., 1991; Cataldo et aI., 1993), rat thecal cells
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(Erickson et at., 1995), and ovine thecal cells (Armstrong et aI., 1996). Similarly, LH
had no effect on IGFBP-2 and -3 mRNA levels in cultured human thecal cells
(Voutilainen et al., 1996) and granulosa ceJls (Giudice et al., 1991). LH also had no
effect on IGFBP-4 production by rat thecal cells (Erickson et aI., 1995). In contrast, LH
decreased IGFBP-3 production by human granulosa cells (San Roman and Magoffin,
1992). These studies suggest that the influence ofLH on IGFBP production may be
species dependent or dependent on whether thecal or granulosa cells have luteinized in
vitro.
For the first time, we have found that cortisol inhibited production ofIGFBP-2/5
and the 20-kDa (IGFBP-4) IGFBP by the granulosa cells with little or no effect on
IGFBP production by the thecal cells. Of the hormones tested, cortisol was the most
influential on granulosa cell IGFBP production, inhibiting IGFBP production in the
presence and absence of insulin. In comparison, cortisol decreased production of the
24-kDa IGFBP (IGFBP-4) by the thecal cells in the absence of insulin, but had no effect
on production of the other IGFBPs (i.e., IGFBP-2, -3, -5). Similarly,IGFBP-4
production was decreased with dexamethasone in cultured human osteoblast cells
(Durham et aI., 1994). In contrast, IGFBP-2 and -4 production increased with
dexamethasone and hydrocortisone application in cultured mouse pancreatic p-cells and
rabbit proximal tubular cells, respectively (Katz et al., 1997; Yap et al.,l997) whereas
dexamethasone had no effect on IGFBP-4 production by cultured human fibroblast cells
(Conover et a1., 1993a). Likewise, IGFBP-3 production was also variable with cortisol
treatments, depending on the cell type. For instance, dexamethasone had no influence
on IGFBP-3 production by human keratinocytes (Wraight and Werther, 1995) but
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decreased production by cultured human fibroblasts (Camacho-Hubner et a1., 1992). In
vivo, IGFBP-3 levels were stimulated by dexamethasone in healthy males (Mien et al.,
1993; 1994). Treatment of cortisol inhibited IGFBP-5 production by cultured fetal rat
osteoblast cells (Gabbitas et aI., 1996) and human fibroblasts (Camacho-Hubner et aI.,
1992). Thus, the specific effect ofcortisol on a particular IGFBP depends on the cell-
type. Because IGFBP production is associated with follicular atresia, the cortisol-
induced decrease in IGFBP production in granulosa and thecal cells may help maintain
or further stimulate follicle growth. In the cow, cortisol increases both insulin- and
IGF-I-induced progesterone and androstenedione production in cultured thecal ceUs
(Spicer and Chamberlain, 1998). Collectively, these results imply that cortisol may be
involved with the maintenance or growth of ovarian follicles in cattle.
Insulin consistently increased IGFBP-5 and the 18-kDa IGFBP (IGFBP-4) by
thecal and granulosa cells, respectively. Similarly, insulin increased production of
IGFBP-4 by cultured human fibroblast cells (Camacho-Hubner et aI., 1992). Insulin's
effect on IGFBP-4 may be dose-dependent because high insulin doses (~ 100 nglmL)
increased IGFBP-4 by human endometrial stromal cells (Irwin et aI., 1995) and rat
hepatocytes (Scharfet at, 1996) and low doses of insulin (~ 10 ng/mL) did not affect
IGFBP-4 levels in human endometrial stromal (Irwin et at, 1995) or neuroblastoma
(Babajko et at, 1997) cells. In contrast to IGFBP-4, high doses of insulin appear to
decrease IGFBP-2 production by rat intestinal epithelial cells (Guo et aI., 1995) and rat
hepatocytes (Scharf et at, 1996). Insulin treatments did not have any significant effect
on IGFBP-5 production by cultured human osteoblast cells (Conover and Kiefer, 1993)
and fibroblasts (Camacho-Hubner et aI., 1992). Similar to what was found for thecal
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cells of the present study, production ofIGFBP-3 protein or mRNA by cultured human
retinal pigment epithelial cells (Feldman and Randolph, 1994), as well as IGFBP-3
protein by cultured human fibroblasts (Camacho-Hubner et aI., 1992) and granulosa
cells (Cataldo et aI., 1993) were not affected by insulin treatments. The discrepancies
observed with the current study versus previous research suggests that the specific
effect of insulin on production of a particular IGFBP may be dependent on cell-type and
concentration of insulin used.
For the first time, an effect of glucagon with.n the ovary has been demonstrated.
Specifically, glucagon blocked the stimulatory effect of insulin on production of
IGFBP-5 by thecal cells and the 18-kDa (IGFBP-4) by granulosa cells. Alone, glucagon
had little or no effect. In the presence of insulin, glucagon also decreased production of
the 24- and 22-kDa IGFBP (lGFBP-4) by thecal cells, and IGFBP-2/5 by granulosa
cells. Although Denver and Nicoll (1994) found no significant effect ofglucagon on
IGFBP-2 and -4 production by primary rat hepatocytes, IGFBP-l levels were decreased.
GH deficient patients administered glucagon experienced increased serum IGFBP-l
levels (Hilding et aI., 1993). Serum insulin and glucose levels transiently increased as
well, but decreased following the IGFBP-l increase. The decrease in insulin would
suggest that glucagon overcomes insulin stimulation of IGFBP-l ~ an observation we
also demonstrated in the current research. Thus, glucagon appears to exert an inhibitory
effect on bovine ovarian IGFBP production in vitro.
Based on the current and previous results, the mechanism by which IGFBP
production is regulated is likely through a network ofhonnones. Because IGFBP
activity decreases during follicular growth and increases during follicular atresia, the
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changes in honnone concentrations during the estrous cycle are likely changing IGFBP
production. This in tum would decrease IGFBP activity and result in an increase in
bioavailable IGF. Because IGF-I and -II remains relatively constant throughout follicle
growth, fluctuations in IGFBP activity during the estrous cycle appear to regulate the
bioavailability ofIGF.
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B
¢::IGFBP-3
¢::IGFBP-2
¢::IGFBP-5
IGFBP-4:
¢::24-kDa
¢::22-kDa
Figure 1: Panel A: representative example of cultured thecal cells under
phase contrast microscopy. Panel B: representative ligand blot of thecal cell
IGFBP production.
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A
B
IGFBP-2/5
.... GFBP-4:
:¢=20-kDa
'¢=18-kDa
Figure 2: Panel A: representative example of cultured granulosa cells under phase
contrast microscopy, Panel B: representative ligand blot ofgranulosa cell IGFBP
production,
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Figure 3. Effect of thecal cell density on IGFBP-3 (A), IGFBP-2 (B), the 27-29-kDa
(IGFBP-5, C), 24-kDa (IGFBP-4, D), and 22-kDa (IGFBP-4, E) IGFBP (arbitrary
densitometric units/I 05 cells/24 h) production by thecal cells. Thecal cells were plated
at densities of .25, .5, 1.0, 1.5,3.0, or 6.0 (x 105) and cultured for 2 days in the presence
of 100t/o FCS as described in Materials and Methods and then treated with serum-free
medium with 100 ng/mL of insulin and 100 ng/mL ofLH for an additional 24 h.
Values are means from two different experiments. Means without a common letter
differ (p < .05).
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Figure 4. Effect of cell density on the 27-34-kDa (IGFBP-2/5, A), 20-kDa (IGFBP-4,
B), and 18-kDa (IGFBP-4,C) IGFBP (arbitrary densitometric units/l0~ cells/24 h)
production by granulosa cells. Granulosa ceUs were plated at densities of 0.25, 0.5, 1.0,
1.5 or 3.0 (x 10~) and cultured for 2 days in the presence of 10% FCS as described in
Materials and Methods and then treated with serum-free medium with 100 ng/mL of
insulin and 50 ng/mL ofFSH for an additional 24 h. Values are means from three
different experiments. Means without a common letter differ (p < .05).
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Figure 5. Effect of insulin, LH, EGF, and bFGF on the 27-29-kDa (IGFBP-5, A) and
22-kDa (IGFBP-4, B) IGFBP production (arbitrary densitometric units/lOS cells/24 h)
by thecal cells from large follicles (~ 8 mm). Thecal cells were cultured for 2 days in
the presence of 10% FCS as described in Materials and Methods and then treated in
serum-free medium with 100 nglmL of insulin (INS), 100 ng/mL ofLH (LH), 100
ng/mL of insulin plus 100 nglmL ofLH (I + L), 10 ng/mL ofEGF plus 100 ng/mL of
insulin (I + E), 10 nglmL of bFGF plus 100 ng/mL of insulin (I + F) or no additions
(CON) for and additional 24 h. Values are means from three separate experiments.
Means without a common letter differ (p < .05).
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Figure 6. Effect of insulin, FSH, EGF, and bFGF on the 27-34-kDa IGFBP (IGFBP-
2/5) production (arbitrary densitometric units/l05 cells/24 h) by granulosa cells from
small follicles (1-5 mm). Granulosa cells were cultured for 2 days in the presence of
1()O!cJ FCS as described in Materials and Methods and then treated in serum-free medium
with 100 nglmL of insulin (INS), 50 nglmL ofFSH (FSH), 100 nglmL of insulin plus
50 ng/mL ofFSH (I + FSH), 10 ng/mL ofEGF plus 100 ng/mL of insulin (I + E), 10
ng/mL ofbFGF plus 100 nglmL of insulin (I + F) or no additions (CON) for an
additional 24 h. Values are means from three separate experiments. Means without a
common letter differ (p < .05).
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Figure 7. Effect of insulin, glucagon, and cortisol on production ofthe 27-29-kDa
(IGFBP-5, A), 24-kDa (IGFBP-4, B), and 22-kDa (IGFBP-4, C) IGFBP (arbitrary
densitometric units/lOS cell&'24 h) by thecal cells from large follicles (~ 8 mm). Thecal
cells were cultured for 2 days in the presence of 10% FCS as described in Materials and
Methods and then treated in serum-free medium with 100 nglmL of insulin (INS), 30
ng/mL of cortisol (COR), 100 ng/mL of insulin plus 30 nglmL of cortisol (I + C), 300
pglmL of glucagon (GLU), 100 nglmL of insulin plus 300 pglmL of glucagon (I + G) or
no additions (CON) for an additional 24 h. Values are means from three separate
experiments. Means without a common letter differ (p < .05).
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Figure 8. Effect of insulin, glucagon, and cortisol on production of the 27-34-kDa
(IGFBP-2/5, A), 20-kDa (IGFBP-4, B), and I8-kDa (IGFBP-4, C) IGFBP (arbitrary
densitometric unitsllO~ cells/24 h) by granulosa cells from small follicles (1-5 mm).
Granulosa cells were cultured for 2 days in the presence of 10% FCS as described in
Materials and Methods and then treated in serum-free medium with 100 ng/mL of
insulin (INS), 30 ng/mL of cortisol (COR), 100 ng/mL of insulin plus 30 ng/mL of
cortisol (I + C), 300 pglmL ofglucagon (GLU), 100 ng/mL of insulin plus 300 pg/mL
of glucagon (1 + G) or no additions (CON) for an additional 24 h. Values are means
from three separate experiments. Means without a common letter differ (p < .05).
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Table 3
Effect ofLH, insulin, EGF, and bFGF on thecal cell proliferation and production of
IGFBP-3, -2 and the 24-kDa IGFBP (IGFBP-4; Experiment 2A)
Arbitrary densitometric units/lO' cells/24 h
Treatment Cell number IGFBP-32 IGFBP-2 24-kDa IGFBP2
(x lOs/well)l
Control 3.211 ± .09S- .333 ± .094- .492 ± .OS2 .505 ± .OS7-
Insulin 4.059 ± .09Sb ab .707 ± .OS2 .754 ± .087bc.493 ± .094
LH 3.294 ± .09S- .496 ± .094ab .50S ± .082 .747 ± .087abc
Insulin + LH 4.026 ± .098b .639 ± .094b .772 ± .082 .S28 ± .087c
Insulin + EGF 6.083 ± .098c .661 ± .094b .605 ± .082 .589 ± .087abc
Insulin + bFGF 6.427 ± .09Sd .713 ± .094b .504 ± .082 ab.531 ± .087
Data are mean ± SE of 3 separate experiments.
IMeans without a common letter differ (p < .05).
2Means without a common letter differ (p < .10).
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Table 4
Effect ofFSH, insulin, EGF, and bFGF on granulosa cell proliferation and production
of the 20-kDa (IGFBP-4) and 18-kDa (IGFBP-4) IGFBP (Experiment 2B)
Arbitrary densitometric units/to' cells/24 h
Treatment Cell number 20-kDa IGFBP 18-kDa IGFBP
(x 1O~/well)1
Control .448 ± .065· .107 ± .024 .083 ± .024
Insulin 1.435 ± .065b .114 ± .024 .098 ± .024
FSH .448 ± .065a .143 ± .024 .134 ± .024
Insulin + FSH 1.537 ± .065b .115 ± .024 .102 ± .024
Insulin + EGF 2.018 ± .065c .105 ± .024 .074 ± .024
Insulin + bFGF 2.072 ± .065c .057 ± .024 .052 ± .024
Data are mean ± SE of3 separate experiments.
IMeans without a common letter differ (p < .05).
-
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Table 5
Effect of insulin, glucagon, and cortisol on thecal cell proliferation and production of
IGFBP-3 and -2 (Experiment 3A)
Arbitrary densitometric unitsll 0'cells/24 h
Treatment Cell number IGFBP-3 IGFBP-i1
(x IOs/well)l
Control 1.796 ± .089a .186 ± .036 .137 ± .024ab
Insulin 2.613 ± .089c .173 ± .036 .186 ± .024b
Glucagon 1.993 ± .089ab .117 ± .036 .100 ± .024'
Cortisol 2.116 ± .089ab .105 ± .036 .094 ± .024'
Insulin + Glucagon 2.272 ± .089b .121±.036 .147 ± .024ab
Insulin + Cortisol 2.870 ± .089c .229 ± .036 .137 ± .024ab
Data are mean ± SE of 3 separate experiments.
IMeans without a common letter differ (p < .05).
2Means without a common letter differ (p < .10).
Table 6
Summary of the effects ofhormone treatments on IGFBP production by
bovine thecal cells..b
Hormone IGFBP-3 IGFBP-2 IGFBP-5 IGFBP-4
(42-44-kDa) (34-kDa) (27-29-kDat (24-kDa) (22-kDa)
Insulina No effect No effect Increasea No effect No effect
L~ No effect No effect No effect No effect No effect
EGpb No effect No effect No effect No effect No effect
bFGF" No effect No effect Decrease No effect Decrease
Glucagonab No effect No effect No effect-{ No effect-{ Decreasebl
Decreaseb Decreaseb No effect-
Cortisolab No effect No effect No effect No effect No effectb{
Decrease-
~ffects are compared with control values (basal).
~ffects are compared with insulin-treated values.
'1'he major IGFBP produced by thecal cells.
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Table 7
Summary ofthe effects of hormone treatments on IGFBP production by
bovine granulosa cellsab
147
Honnone
Insulin·
FSHab
EG~
bFGFb
Glucagonab
Cortisolab
IGFBP-2/5 IGFBP-4
(27-34-kDat 20-kDa 18-kDa
DecreaseJNo effect No effect Increase
No effect/Decreaseb No effect No effect
Decrease No effect No effect
Decrease No effect No effect
No effeeta/Decreaseb Decrease No effect·IDecreaseb
Decrease Decrease No effect·/Decreaseb
aEffects are compared with control values (basal).
~ffects are compared with insulin-treated values.
c-rhe major IGFBP produced by granulosa cells.
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CHAPTER IV
Summary and Conclusions
Folliculogenesis is a complex and dynamic process. A multitude of factors
interact to ultimately result in one selected follicle to ovulate while the remaining cohort
of follicles will regress and die. During normal cyclicity, IGF-I enhances steroidogenesis
of the granulosa and thecal cells although ovarian IGF-I levels remain constant.
However, serum IGF-I concentrations decreases in non-cyclic cows, suggesting that IGF-
I is important for sustained reproduction. Indeed, IGF-I as well as its IGFBPs do
influence steroidogenesis of the follicle. The ultimate question however remains to be
determined. That is, what are the factors that determine selection of the follicle?
The present study evaluated the effects of hormones applied to cultured thecal or
granulosa cells to determine the hormonal regulation ofIGFBP production. IGFBP-2, -4,
and -5 were produced by the bovine thecal and granulosa cells. IGFBP-3 was also
produced by the thecal cells, but not the granulosa cells. Moreover, glucagon, cortisol,
insulin, bFGF, and EGF all appeared to impact IGFBP production but each IGFBP was
influenced differentially by a different subset of hormones. However, the actual
hormone, or complex of hormones which controls IGFBP synthesis was not resolved.
The conclusion to obtain from this work is that IGFBPs are indeed influenced by
hormones with no one IGFBP influenced synchronously with another. Through a
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network of hormones, and possibly proteases, IGFBPs levels are modulated through the
estrous cycle, thus detennining the bioavailability ofIGF-I and ultimately, follicle
growth. Thus, by understanding the factors that determine follicle selection. and
ultimately ovulation. the loss of productivity from non-cyclic cattle will subside.
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